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FIGURE 1 
Time Course of Effect of ZZ-16-1 C 
Rodent Model of Tonic Inflammatory Pain 
(Formalin Test) 
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FIG. 2 
Dose Response Effect of ZZ -16-1 C 
Rodent Model of Tonic Inflammatory Pain 
(Formalin Test) 
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Vincristine*-lnduced Neuropathic Pain in the Rat 
a; Paw Pressure Test (mechanical hyperalagesia) 
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Vincristine*-lnduced Neuropathic Pain in the Rat 
Von Frey Test (Tactile Allodynia) 
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Figure 4 
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Effect of Vincristine* on Body Weight in the Rat 
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HIS-QUATERNARY AMMONIUM SALTS AS 
PAIN MODULATING AGENTS 
FIELD OF THE INVENTION 
The invention relates to his-quaternary ammonium salts 
and their use as agents for pain modulation, treatment, 
reversal and/or prevention of inflammatory pain, neuro-
pathic pain or nociceptive pain. 
BACKGROUND OF THE INVENTION 
The treatment of pain is a critical health issue. Acute (e.g., 
postoperative pain) and chronic (e.g., arthritis, low back, 
cancer) pain affects tens of millions of people annually in the 
US. Each year some 30 million people visit a physician with 
a complaint of a painful condition. Some 10% of these 
patients are seen with chronic pain as their main complaint. 
The financial loss due to pain has been estimated to exceed 
100 billion dollars a year as a result of medical fees, 
decreased productivity, litigation and the cost of drugs. New 
therapeutic agents with broader efficacy, for nociceptive, 
neuropathic and mixed nociceptive-neuropathic pain syn-
dromes, and with fewer side effects would result in signifi-
cant societal benefit. 
Pain can be broadly divided into two categories: nocice-
ptive and neuropathic pain. Nociceptive pain occurs as a 
result of activation of peripheral nociceptors, actually free 
nerve endings by noxious stimuli (heat, pressure, inflamma-
tory mediators). Examples of nociceptive pain include post-
surgical pain, inflammatory pain (e.g., arthritis) and low 
back pain. Such a pain is often described as "a constant, dull, 
aching pain". Neuropathic pain occurs as a result of damage 
to the peripheral or central nervous system. Examples of 
neuropathic pain include radiculopathy (e.g., disc impinge-
ment on a nerve), complex regional pain syndrome (CRPS 
I, II), diabetic peripheral neuropathy or central pain (stroke, 
spinal cord injury, multiple sclerosis). Patients typically 
describe neuropathic pain as "burning and tingling" in 
nature. It is characterized by hyperalgesia (increased painful 
response to a noxious stimulus) and allodynia (pain to a 
previously non-noxious stimulus). 
2 
gastrointestinal toxicity, was thought to be an advance in 
NSAID pharmacology. Nonetheless, these agents still have 
low efficacy and evidence is now available linking them to 
significant cardiovascular events including stroke and myo-
cardial infarction following chronic use. This has resulted in 
the removal of both rofecoxib and valdecoxib from the 
market. No truly efficacious agent exists for the treatment of 
neuropathic pain. GABA-pentin (Neurontin®), an anticon-
vulsant, has found use for some neuropathic pain syndromes 
10 (e.g., diabetic peripheral neuropathy, postherpetic neural-
gia), but it still has limited efficacy. Duloxetine (Cym-
balta®), an antidepressant, has recently been approved for 
the treatment of diabetic peripheral neuropathy. However, it 
has limited efficacy and usefulness for other neuropathic 
15 pain states. The N-methyl-d-aspartate (NMDA) receptor 
antagonists (e.g., ketamine) have been proposed for the 
treatment of neuropathic pain. Their general use is imprac-
tical given the marked side effects including sedation, psy-
chosis and motor impairment. The limitations of the cur-
20 rently available therapies clearly demonstrate the need for a 
broad spectrum new class of efficacious and safe analgesic 
drugs for the treatment of nociceptive and neuropathic pain. 
Given the need for more effective, less toxic, analgesic 
drugs, a great deal of emphasis has been placed on identi-
25 :tying novel molecular targets that could form the basis for 
new analgesics. One of the promising new targets is the 
neuronal nicot1mc acetylcholine receptor (nAChR). 
nACHR's play an important role in the control of pain and 
thus drugs acting at the nicotinic receptor, as agonists, partial 
30 agonists or antagonists may be expected to have analgesic 
properties. The his-quaternary ammonia salts of the inven-
tion are thought to interact with the nACHR. Nicotinic 
receptor drugs have been shown to have a broad spectrum of 
analgesic activity in several preclinical models of pain of 
35 nociceptive and neuropathic origin. This includes acute 
thermal pain models (tail flick, hot plate), inflammatory pain 
models (formalin or carrageenan injection into the paw) and 
nerve injury (neuropathic pain) models (spinal or sciatic 
nerve ligation). Both anti-hyperalgesic and anti-allodynic 
40 effects were observed in the neuropathic pain models. 
In many pain patients, in particular those with chronic 
pain conditions of both malignant (cancer-related pain) and 
non-malignant origin, pain is inadequately managed with 45 
currently available drugs. Available drugs are simple modi-
fications (e.g., extended release) of drugs from classes which 
have been available for decades including the opioids, 
nonsteroidal anti-inflammatory agents (NSAID's) or various 
adjuvants (antidepressants, anticonvulsants) initially 50 
approved for other uses besides pain. Opioids (e.g., mor-
phine, oxycodone) are often successfully used for the treat-
ment of moderate to severe nociceptive pain. Chronic neu-
ropathic pain is much less responsive to opioids. Use of 
opioid analgesics is associated with a broad range of sig- 55 
nificant side effects including cognitive impairment, respi-
ratory depression and constipation. In addition, long-term 
opioid dosing results in the development of tolerance to the 
analgesic effect, drug abuse and dependence. The NSAID's 
(e.g., ibuprofen) act by inhibition of the cyclo-oxygenase 60 
(Cox-1 ,2) enzyme. They are especially useful in nociceptive 
pain of inflammatory origin (e.g., arthritis). However, the 
NSAID's have limited efficacy when compared to the opi-
oids. In addition, NSAID's have significant side effects 
(renal, gastrointestinal, cardiovascular). The discovery of 65 
the Cox-2 selective agents (e.g., rofecoxib-Vioxx®; cele-
coxib-Celebrex®; valdecoxib-Bextra®) which have far less 
Thus, it appears that nicotine drugs have promise as 
analgesic agents for the treatment of several types of clinical 
pain, specifically nociceptive, neuropathic and inflammatory 
pain. 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the 
following structure which are useful in treating inflamma-
tory pain, neuropathic pain or nociceptive pain are provided. 
X 2 8EBR1-H2 C-L
1-Q-L2-CH2-R
2EB8X 1 (1) 
X18 and X28 are each independently an organic or 
inorganic anion. 
Q is selected from phenylene, 
---CH=CH-, ---CH=CH---CH=CH-, 
---C C---C C-, -O-(CH2 ) 2-0-, 
( CH2 ) 2---0-( CH2 ) 2---0-. 
biphenylene, 
-C C-, 
and -0-
L 1 and L 2 are each independently selected from alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub-
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary-
lalkynyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic; SOY1 , S02Y
1
, S020Y
1 or S02NHY\ where 
Y1 is selected from hydrogen, lower alkyl, alkenyl, alkynyl 
or aryl, and where Y 1 is not hydrogen in SOY1 and ifY1 is 
US 9,499,518 B2 
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alkenyl or alkynyl, the site ofunsaturation is not conjugated 
with a heteroatom; COY2, where Y2 is selected from hydro-
gen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, 
substituted alkylaryl, arylalkyl, substituted arylalkyl, arylal-
kenyl, substituted arylalkenyl, arylalkynyl, substituted ary-
lalkynyl, heterocyclic, or substituted heterocyclic, and 
where ifY2 comprises alkenyl or alkynyl, the site ofunsatu-
ration is not conjugated with the carbonyl group; OY3, 
where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where ifY3 comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
with the oxygen; NY4Ys where Y4 and ys are each inde-
pendently selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkyisulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where if Y4 or ys 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the nitrogen; SY6, where Y6 is selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub-
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, or substituted heterocyclic, and where if Y6 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the sulfur. 
R1 and R2 are each independently five or six membered 
nitrogen containing rings as shown in formulas (IIA) and 
(liB). 
(IIA) 
(liB) 
A 1 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 1 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R3 is absent, and when A 1 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
4 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both Rs and R6 are absent. 
A3 is carbon, nitrogen, sulfur or oxygen, provided that 
when A3 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R7 is absent, and when A3 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R7 and R8 are absent. 
A 4 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 4 is a carbon and joins a ring atom with an unsatu-
10 rated bond or is a nitrogen, R9 is absent, and when A 4 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R9 and RIO are absent. 
As is carbon, nitrogen, sulfur or oxygen, provided that 
when As is a carbon and joins a ring atom with an unsatu-
15 rated bond or is a nitrogen, R11 is absent, and when As is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R11 and R12 are absent. 
A 6 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 6 is a carbon and joins a ring atom with an unsatu-
20 rated bond or is a nitrogen, R 14 is absent, and when A 6 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R14 and R1s are absent. 
A7 is carbon, nitrogen, sulfur or oxygen, provided that 
when A7 is a carbon and joins a ring atom with an unsatu-
25 rated bond or is a nitrogen, R16 is absent, and when A7 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 16 and R 17 are absent. 
A 8 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 8 is a carbon and joins a ring atom with an unsatu-
30 rated bond or is a nitrogen, R18 is absent, and when A8 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R18 and R19 are absent. 
A9 is carbon, nitrogen, sulfur or oxygen, provided that 
when A9 is a carbon and joins a ring atom with an unsatu-
35 rated bond or is a nitrogen, R20 is absent, and when A9 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R20 and R21 are absent. 
R13 or R22 is absent when any of the bonds to the 
ammonium nitrogen is unsaturated, and R13 or R22 is a 
40 straight chain or branched alkyl group of four carbons or 
fewer when all of the bonds to the ammonium nitrogen are 
saturated. 
R3, R4, Rs, R6, R7, R8, R9, RIO, Ru, andR12, orR14' R1s, 
R16, R17, R18, R19, R20, and R21 , when present, are each 
45 independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
50 stituted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, orR4 andRs togetherwithA1 andA2, or 
Rs and R7 together withA2 andA3, or R1s and R16 together 
with A6 and A7, or R16 and R18 together with A7 and A8 
independently form a three to eight member cyclolkane, 
55 substituted cycloalkane, cycloalkene, substituted cycloalk-
ene, aryl, substituted aryl, heterocycle with one to three 
hetero atoms of nitrogen, oxygen or sulfur in the ring, or 
substituted heterocycle with one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and when all of the 
60 bonds to the ring ammonium nitrogen are saturated, then any 
ofR3, R4, Rs, R6, R7, R8, R9, RIO, Ru, Rl2, Rl3, R14, R1s, 
R16, R17, R18, R19, R20, R21 or R22 which is attached to the 
ammonium nitrogen is a straight or branched alkyl group of 
four carbons or fewer. 
A2 is carbon, nitrogen, sulfur or oxygen, provided that 65 
when A2 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, Rs is absent, and when A2 is 
In another embodiment, a composition is provided com-
prising a pharmaceutically acceptable carrier and a com-
pound as described above. 
US 9,499,518 B2 
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In another embodiment, a method is provided for selec-
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-
malian subject in need thereof. 
6 
The term "lower alkyl" refers to straight or branched 
chain alkyl radicals having in the range of 1 to 4 carbon 
atoms. 
The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 
refers to alkyl radicals further bearing one or more substitu-
ents including, but not limited to, hydroxy, alkoxy (of a 
lower alkyl group), mercapto (of a lower alkyl group), aryl, 
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino, 
carboxyl, carbamate, sulfonyl, and sulfonamide. 
In another embodiment, a method is provided for modu-
lating, preventing, treating and/or reversing acute, chronic or 
cancer pain of central and/or peripheral origin that is 
referred to as nociceptive, neuropathic, visceral, inflamma-
tory or somatic in nature comprising administering a thera- 10 
peutically effective amount of a compound as described 
above to a mmalian subject in need thereof. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
15 
or more substituents as set forth above. BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 shows the time course of the analgesic effects of 
ZZ-1-61 C in the rodent formalin persistent inflmatory 
pain model following intraperitoneal administration. Data 
are mean±SEM (n=6 rats/dose). 
FIG. 2 shows the dose response of the analgesic effects of 
ZZ-1-61C in the rodent persistent inflmatory pain model 
following intraperitoneal administration. Data are mean 
S.E.M. (n=6 rats/dose). 
FIG. 3 provides a graph showing the anti-hyperalgesic 
effects of ZZ-1-61C in the paw pressure test. 
FIG. 4 provides a graph showing the anti-allodynic effect 
of ZZ-1-61C in a rodent model of chemotherapy-induced 
pain by determining paw withdrawal frequency. 
FIG. 5 provides a graph showing the effect of ZZ-1-61C 
on the toxicity (body weight loss) of vineristine in a rodent 
model of chemotheraopy-induced pain. 
DETAILED DESCRIPTION OF INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, 
and is in no way intended to limit the scope of the present 
invention as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms "a," "an," and "the" include plural 
references unless the context clearly dictates otherwise. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meanings as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. All publications cited herein are incor-
porated herein by reference in their entirety for the purpose 
of describing and disclosing the methodologies, reagents, 
and tools reported in the publications that might be used in 
connection with the invention. Nothing herein is to be 
construed as an admission that the invention is not entitled 
to antedate such disclosure by virtue of prior invention. 
The term "agonist" refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term "partial agonist" refers to a substance which 
interacts with and activates a receptor to a lesser degree than 
an agonist. 
The term "antagonist" refers to a substance which inter-
acts with and decreases the extent or duration of a physi-
ological response of that receptor. 
The terms "disorder," "disease," and "condition" are used 
inclusively and refer to any status deviating from normal. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon 
double bond and having 2 to 19 carbon atoms, and "substi-
tuted alkenyl" refers to alkenyl groups further bearing one or 
20 more substituents as set forth above. 
The term "alkynyl" refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon 
triple bond and having 2 to 19 carbon atoms, and "substi-
tuted alkynyl" refers to alkynyl moieties further bearing one 
25 or more substituents as set forth above. 
The term "aryl" refers to aromatic groups having 6 to 24 
carbon atoms, and "substituted aryl" refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term "alkylaryl" refers to alkyl-substituted aryl 
30 groups, and "substituted alkylaryl" refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
35 
The term "arylalkyl" refers to aryl-substituted alkyl 
groups, and "substituted arylalkyl" refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term "arylalkenyl" refers to aryl-substituted alkenyl 
groups, and "substituted arylalkenyl" refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term "arylalkynyl" refers to aryl-substituted alkynyl 
40 groups, and "substituted arylalkynyl" refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term "heterocyclic" refers to cyclic moieties contain-
ing one or more heteroatoms as part of the ring structure and 
45 having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term "acyl" refers to alkyl-carbonyl groups, and 
"substituted acyl" refers to acyl groups further bearing one 
50 or more substituents as set forth above. 
The term "halogen" refers to fluoride, chloride, bromide 
or iodide groups. 
It is understood that in all substituted groups defined 
above, polymers arrived at by defining substituents with 
55 further substituents to themselves (e.g. substituted aryl hav-
ing a substituted aryl group as a substituent which is itself 
substituted with a substituted aryl group, etc.) are not 
intended for inclusion herein. In such cases, the maximum 
number of such substituents is three. That is to say that each 
60 of the above definitions is constrained by a limitation that, 
for example, substituted aryl groups are limited to -substi-
tuted aryl-(substituted aryl)-substituted aryl. 
Compounds of the present invention are his-quaternary 
ammonium salts disclosed in PCT/US2007/011635, filed 
65 May 14, 2007 corresponding to Formula (1): 
X 2 8EBR1-H2 C-L
1-Q-L2-CH2-R
2EB8X 1 (1) 
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X18 and X28 are each independently an organic or 
inorganic anion. 
Q 1s selected from phenylene, 
-CH=CH-, ---CH=CH---CH=CH-, 
-C==C---C C-, ---O-(CH2 ) 2-0-, 
(CH2 ) 2-0-(CH2 ) 2---0-. 
biphenylene, 
---C C-, 
and -0- 5 
L1 and L2 are each independently selected from alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub- 10 
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary-
lalkynyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic; SOY\ S02 Y\ S020Y
1 or S02 NHY
1 where 
Y1 is selected from hydrogen, lower alkyl, alkenyl, alkynyl 15 
or aryl, and where Y1 is not hydrogen in SOY1 and ifY1 is 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
with a heteroatom; COY2 , where Y2 is selected from hydro-
gen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, 20 
substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, 
substituted alkylaryl, arylalkyl, substituted arylalkyl, arylal-
kenyl, substituted arylalkenyl, arylalkynyl, substituted ary-
lalkynyl, heterocyclic, or substituted heterocyclic, and 
where ifY2 comprises alkenyl or alkynyl, the site ofunsatu- 25 
ration is not conjugated with the carbonyl group; OY3 , 
where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal- 30 
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where ifY3 comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
35 
with the oxygen; NY4Ys, where Y4 and ys are each inde-
pendently selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal- 40 
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where if Y4 or ys 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the nitrogen; SY6 , where Y6 is selected 45 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub-
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 50 
heterocyclic, or substituted heterocyclic, and where if Y6 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the sulfur. 
R1 and R2 are each independently five or six membered 
nitrogen containing rings as shown in formulas (IIA) and 55 
(liB). 
8 
-continued 
(liB) 
A 1 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 1 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R3 is absent, and when A 1 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
A2 is carbon, nitrogen, sulfur or oxygen, provided that 
when A2 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, Rs is absent, and when A2 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both Rs and R6 are absent. 
A3 is carbon, nitrogen, sulfur or oxygen, provided that 
when A3 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R7 is absent, and when A3 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R7 and R8 are absent. 
A 4 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 4 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R9 is absent, and when A 4 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R9 and R 10 are absent. 
As is carbon, nitrogen, sulfur or oxygen, provided that 
when As is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R11 is absent, and when As is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R11 and R12 are absent. 
A 6 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 6 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R 14 is absent, and when A 6 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R14 and R1s are absent. 
A7 is carbon, nitrogen, sulfur or oxygen, provided that 
when A7 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R16 is absent, and when A7 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 16 and R 17 are absent. 
A 8 is carbon, nitrogen, sulfur or oxygen, provided that 
when A 8 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R18 is absent, and when A8 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R18 and R19 are absent. 
A9 is carbon, nitrogen, sulfur or oxygen, provided that 
when A9 is a carbon and joins a ring atom with an unsatu-
rated bond or is a nitrogen, R20 is absent, and when A9 is 
sulfur or oxygen or joins a ring atom with an unsaturated 
bond and is a nitrogen, both R20 and R21 are absent. 
R13 or R22 is absent when any of the bonds to the 
ammonium nitrogen is unsaturated, and R13 or R22 is a 
straight chain or branched alkyl group of four carbons or 
fewer when all of the bonds to the monium nitrogen are (IIA) 
60 saturated. 
R3 , R4 , Rs, R6 , R7 , R8 , R9 , R10, R11 , andR12, orR14, R1s, 
R16, R17, R18, R19, R20 , and R21 , when present, are each 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
65 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
US 9,499,518 B2 
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stituted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, or R4 and R5 together withA1 andA2, or 
R5 and R7 together withA2 andA3, or R15 and R16 together 
with A6 and A7 , or R16 and R18 together with A7 and A8 
independently form a three to eight member cyclolkane, 5 
substituted cycloalkane, cycloalkene, substituted cycloalk-
ene, aryl, substituted aryl, heterocycle with one to three 
hetero atoms of nitrogen, oxygen or sulfur in the ring, or 
substituted heterocycle with one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and when all of the 10 
bonds to the ring ammonium nitrogen are saturated, then any 
ofR3, R4, R5, R6, R7 , R8, R9, R10, R11 , R12, R13 , R14, R15 , 
R16, R17, R18, R19, R20, R21 or R22 which is attached to the 
ammonium nitrogen is a straight or branched alkyl group of 
four carbons or fewer. 15 
For example, R1 and R2 include pyrrole, pyrrolidine, 
pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiaz-
ole, oxadiazole, oxatriazole, dioxazole, 1 ,2,3-triazole, 1 ,2, 
4-triazole, pyridine, pyrimidine, piperidine, quinoline, tet-
rahydroquinoline, isoquinoline, tetrahydroisoquinoline, 20 
pyrazine, piperazine, pyridazine, tnazme, oxazine, 
phenazine, pteridine, benzoxazine, phthalazine, naphthri-
dine, quinoxaline, quinazoline, ciunoline, quinuclidine, ben-
zothiazole, benzisoxazole, benzoxazole, indazole, pyrano-
pyrrole, cyclopentapyridine, benzimidazole, isoindole, 25 
3H-indole, indolene and triazine. 
10 
ents. For example, possible rings include benzene, pyridine, 
pyran, indene, isoindene, benzofuran, isobenzofuran, benzo 
[b ]thiophene, benzo[ c ]thiophene, indole, indolenine, isoin-
dole, cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, inda-
zole, indoxazine, benzoxazole, anthranil, naphthalene, 
tetralin, decalin, chromene, coumarin, chroman-4-one, iso-
coumarin, isochromen-3-one, quinoline, isoquinoline, cin-
noline, quinazoline, naphthyrdine, pyrido[3,4-b ]-pyridine, 
pyridol[3,2-b ]pyridine, pyrido[ 4,3,-b ]-pyridine, benzox-
azine, anthracene, phenanthrene, phenalene, fluorene, cara-
zole, xanthene, acnidine, octahydro-[1]pyridine, 1-methyl-
octahydro-[1]pyridine, octahydroindole, 
1-methyloctahydro-indole, octahydro-cyclopenta[b ]pyrrole, 
1-methyloctahydro-cyclopenta[b ]pyrrole, decahydroquino-
line, and 1-methyldecahydroquinoline. 
X18 and X28, for example F-, Cl-, Br-, I-, N02 -, HS04 -, 
S04-, HP04-, P04
2-, methanesulfonate, trifluromethane 
sulfate, p-toluenesulfonate, benzenesulfonate, salicylate, 
proprionate, ascorbate, aspartate, fumarate, galactarate, 
maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tartrate, oxalate, succinate, or similar pharmaceu-
tically acceptable organic acid addition salts, including the 
pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences volume 66, page 2, 1977, which 
are hereby incorporated by reference. The above salt forms 
may be in some cases hydrates or solvates with alcohols and 
other solvents. 
In a compound of Formula (I), preferably R1 and R2 are 
substituted, six-membered, aromatic rings. More preferably, 
R1 and R2 are substituted pyridinium rings. In other pre-
ferred embodiments, R1 and R2 are quinoline, isoquinoline, 
tetrahydroquinoline or tetrahydroisoquinoline. 
In a compound of Formula (I), preferably R13 is absent. 
In a compound of Formula (I), preferably R3, R4, R5, R6, 
R7 , R8, R9, RIO, R11 or R12 is absent or is hydrogen, alkyl, 
hydroxyalkyl, halo, phenyl or 1-alkyl-2-pyrrolidinyi. More 
preferably, R3, R4, R5, R6, R7 , R8, R9, RIO, R11 or R12 is 
absent or is hydrogen, methyl, ethyl, propyl, butyl, 
hydroxymethyl, hydroxyethyl, hydroxypropyl, bromo, phe-
nyl or 1-methyl-2-pyrrolidinyl. 
In a compound of Formula (I), preferably Q is phenylene, 
biphenylene, ---CH=CH---CH=CH-, ---C C-
C C- and ---O-(CH2)2-0-(CH2)2-0-. 
In a compound of Formula (I), preferably L 1 and L 2 are 
the same and are ---CH2-, -(CH2)2-, -(CH2)3-, 
-(CH2)4-, ---C C-, ---CH2---C C- or -(CH2)2-
C C-. 
In a compound of Formula (I), preferably X1 SYMBOL 
and X2 SYMBOL are halogens. More preferably, X1 SYM-
BOL and X2 SYMBOL are chloride or bromide. 
In another embodiment, the compound of Formula (I) is 
defined wherein -L1-Q-L2- is -(CH2)4-1,2-phenylene-
(CH2)4-, -(CH2)4-1,3-phenylene-(CH2)4-, -(CH2k1, 
4-phenylene-(CH2)3-, -(CH2)2-4,4'-biphenylene-
(CH2)2-, -(CH2)2---C C-1,2-phenylene-C C-
(CH2)2-, -(CH2)2---C C-1,3-phenylene-C C-
(CH2)2-, -CH2-C C-1,4-phenylene-C C-CH2-, 
---C C-4,4'-biphenylene-C C-, -(CH2)3-
CH=CH-CH=CH-(CH2)3-, -(CH2)3---C C-
C C-(CH2)3- or ---CH2---0-(CH2)2---0-(CH2)2-
As another example, R3, R4, R5, R6, R7 , R8, R9, RIO, R11 , 
R12, R14, R15 , R16, R17, R18, R19, R20, and R21 , include 
hydrogen, methyl, ethyl, propyl, butyl, hydroxymethyl, 
hydroxyethyl, hydroxypropyl, trifluoromethyl, chloro, 30 
bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine (for 
example where the alkyl chain is methyl, ethyl or propyl), 
unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for 
example where the alkyl chain is methyl, ethyl or propyl), 
aziridine, N-methyl aziridine, azetidine, N-methyl azetidine, 35 
unsaturated azetidine, unsaturated N-methyl azetidine, pip-
eridine, N-methyl piperidine, unsaturated piperidine, 
unsaturated N-methyl piperidine, azepane, N-methyl 
azepane, unsaturated azepane, unsaturated N-methyl 
azepane, azocane, N-methyl azocane, unsaturated azocane, 40 
unsaturated N-methyl azocane, 1-aza-bicyclo [3.2.1] octane, 
1-aza-bicyclo [2.2.1] heptane, 8-methyl-8-aza-bicyclo 
[3.2.1] octane, 1-aza-tricyclo [3.3.1.13,7] decane, methyl 
cycloalkyl, methyl substituted cycloalkyl, methyl pyrroli-
dine, methyl N-alkyl pyrrolidine (for example where the 45 
alkyl chain is methyl, ethyl or propyl), methyl unsaturated 
pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for 
example where the alkyl chain is methyl, ethyl or propyl), 
methyl aziridine, methyl N-methyl aziridine, methyl azeti-
dine, methyl N-methyl azetidine, methyl unsaturated azeti- 50 
dine, methyl unsaturated N-methyl azetidine, methyl piperi-
dine, methyl N-methyl piperidine, methyl unsaturated 
piperidine, methyl unsaturated N-methyl piperidine, methyl 
azepane, methyl N-methyl azepane, methyl unsaturated 
azepane, methyl unsaturated N-methyl azepane, methyl azo- 55 
cane, methyl N-methyl azocane, methyl unsaturated azo-
cane, methyl unsaturated N-methyl azocane, methyl-1-aza-
bicyclo [3.2.1] octane, methyl-1-aza-bicyclo [2.2.1] 
heptane, 8-methyl-8-aza-bicyclo [3 .2.1] octane, and methyl-
1-aza-tricyclo [3.3.1.13'7] decane. 
As a further example, when R4 and R5 together with A1 
andA2, or R5 and R7 togetherwithA2 andA3, or R15 andR16 
togetherwithA6 andA7 , or R16 andR18 togetherwithA7 and 
A8 independently form a three to eight-membered ring, that 
ring may be a heterocycle containing up to three hetero 65 
atoms (for example nitrogen, oxygen or sulfur) in the ring, 
and further may be substituted with one or more substitu-
60 O---CH2-, R
1 and R2 are pyridinium rings, R3 is hydrogen 
or methyl, R5 is hydrogen, methyl, ethyl, butyl, phenyl, 
1-methyl-2-pyrrolidinyl, bromo, hydroxymethyl or 
hydroxypropyl, R7 is hydrogen or methyl, R9 is hydrogen or 
methyl, R11 is hydrogen, and X1 and X2 are chloride or 
bromide. 
In another embodiment, the compound of Formula (I) is 
defined wherein -L1-Q-L2- is -(CH2)4-1,2-phenylene-
US 9,499,518 B2 
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(CH2)4-, -(CH2)4 -1,3-phenylene-(CH2)4-, -(CH2k1, 
4-phenylene-(CH2)3-, -(CH2)2-4,4'-biphenylene-
(CH2)2-, -(CH2)2---C C-1,2-phenylene-C C-
(CH2)2-, -(CH2)2---C C-1,3-phenylene-C C-
(CH2)2-, ---CH2-C C-1,4-phenylene-C C-CH2-, 5 
-C==C-4,4'-biphenylene-C C-, -(CH2)3-
CH=CH-CH=CH-(CH2)3-, -(CH2)3---C C-
C C-(CH2)3- or -CH2-0-(CH2)2---0-(CH2)2-
0-CH2-, R1 and R2 are quinoline, isoquinoline, 
tetrahydroquinoline or tetrahydroisoquinoline, and X1 and 10 
X2 are chloride or bromide. 
Exemplary compounds of the present invention include: 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-[3-(2'-5-1-
methyl-pyrrolidin-2-yl)-pyridinium] dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-{ 2-methyl-1- 15 
pyridinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(3-methyl-
pyridinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1 s 12-diyl)-bis-( 4-methyl-
pyridinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetra-
hydro-quinolinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetra-
hydro-isoquinolinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(2,4-dim-
ethyl-pyridinium) dibromide; 
cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(3,4-dim-
ethyl-pyridinium) dibromide; 
20 
25 
12 
1 ,2-bis-[ 5-(2-methy 1-pyridinium )-pentyl]-benzene 
mide; 
1,2-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene 
mide; 
dibro-
dibro-
1 ,2-bis-[ 5-( 4-methyl-pyridinium)-pentyl]-benzene dibro-
mide; 
1 ,2-bis-[ 5-(2,4-dimethyl-pyridinium )-penty 1]-benzene 
dibromide; 
1 ,2-bis-[ 5-(3 ,4-dimethyl-pyridinium )-penty 1]-benzene 
dibromide; 
1 ,2-bis-[ 5-(3,5-methyl-pyridinium)-pentyl]-benzene dibro-
mide; 
1 ,2-bis-( 5-quinolinium-pentyl)-benzene dibromide; 
1 ,2-bis-( 5-isoquinolinium -pentyl)-benzene dibromide; 
1 ,2-bis-( 5-S-nicotinium-pentyl)-benzene dibromide; 
1 ,2-bis-[ 5-(3-n-butyl-pyridinium)-pentyl]-benzene dibro-
mide; 
1 ,2-bis-[ 5-(3-bromo-pyridinium )-penty !]-benzene 
mide; 
1 ,2-bis-( 5-pyridinium-pentyl)-benzene dibromide; 
dibro-
1 ,3-bis-[ 5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-[ 5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-[ 5-( 4-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-[ 5-(2,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; cis-cis-N,N'-( dodeca-5, 7 -diene-1, 12-diyl)-bis-(3,5-dim-
ethyl-pyridinium) dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-[3-(2'-S-1-methyl-
pyrrolidin-2-y 1)-pyridinium] dibromide; 
30 1 ,3-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-(2-methylpyri-
dinium) dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-(3-methylpyri-
dinium) dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-( 4-methylpyri-
dinium) dibromide; 
N,N'- [ 1 ,4-pheny lenedi -( 4-butany I) ]-bis-(3-ethy lpyridinium) 
dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-( 5,6, 7,8-tetrahydro-
quinolinium) dibromide; 
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-( 5,6, 7,8-tetrahy-
droisoquinolinium) dibromide; 
1 ,3-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-( 5-quinolinium-pent-1-ynyl)-benzene dibromide; 
35 1 ,3-bis-(5-isoquinolinium-pent-1-ynyl)-benzene dibromide; 
1 ,3-bis-( 5-S-nicotinium-pent-1-ynyl)-benzene dibromide; 
40 
1 ,3-bis-[ 5-(3-n-butyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-[ 5-(3-phenyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,3-bis-[ 5-pyridinium-pent-1-ynyl)-benzene dibromide; 
1 ,3-bis-[ 5-(2-methyl-pyridinium)-pentyl]-benzene dibro-
mide; 
1,3-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene dibro-
N,N'-[1 ,4-phenylenedi-( 4-butanyl)]-bis-[3-(3-hydroxy-pro- 45 
pyl)-pyridinium] dibromide; 
mide; 
1,3-bis-[5-(4-methyl-pyridinium)-pentyl]-benzene dibro-
N,N'- [ 1 ,4-pheny lenedi -( 4-butany I) ]-bis-(2,4-dimethylpyri-
dinium) dibromide; 
N,N'-[1 ,4-phenylenedi-{ 4-butanyl) ]-bis-(3,4-dimethylpyri-
dinium) dibromide; 
N,N'-[1 ,4-phenylenedi-{ 4-butanyl) ]-bis-(3,5-dimethylpyri-
dinium) dibromide; 
1 ,2-bis-[ 5-(2-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-[ 5-(3-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-[ 5-( 4-methyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-[ 5-(2,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-benzene 
dibromide; 
1 ,2-bis-( 5-quinolinium-pent-1-ynyl)-benzene dibromide; 
1 ,2-bis-( 5-isoquinolinium-pent-1-ynyl)-benzene dibromide; 
1 ,2-bis-( 5-S-nicotinium -pent-1-ynyl)-benzene dibromide; 
mide; 
1 ,3 -bis-[ 5-(2,4-dimethyl-pyridinium )-penty 1]-benzene 
dibromide; 
50 1 ,3-bis-[ 5-(3,4-dimethyl-pyridinium)-pentyl]-benzene 
dibromide; 
1 ,3 -bis-[ 5-(3 ,5 -dimethyl-pyridinium )-penty 1]-benzene 
dibromide; 
1 ,3-bis-( 5-quinolinium-pentyl)-benzene dibromide; 
55 1 ,3-bis-(5-isoquinolinium-pentyl)-benzene dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[3-(2'-S-1-
methyl-pyrrolidin-2-yl)-pyridinium] dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(3,5-dimeth-
ylpyridinium) dibromide; 
60 N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(3,4-dimeth-
ylpyridinium) dibromide; 
65 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-(2,4-dimeth-
ylpyridinium) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[3-(3-hy-
droxy -propyl)-pyridinium] dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(3-propanyl) ]-bis-[ 5,6, 7,8-tet-
rahydroquinolinium ]dibromide; 
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N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(3-propanyl)]-bis-[ 5,6, 7,8-tet-
rahydroisoquinolinium ]dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(3-propanyl)]-bis-( 4-methyl-
pyridinium) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(3-propanyl)]-bis-(3-methy-
ipyridinium) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(3-propanyl)]-bis-(2-methyl-
pyridinium) dibromide; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis-[3-(2'-
S-1-methyl-pyrrolidin-2-yl)-pyridinium ]dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(2-
methylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(3-
methylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis( 4-
methylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(5,6, 7, 
8-tetrahydroquinolinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(5,6, 7, 
8-tetrahydroisoquinolinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis-[3-(3-
hydroxypropy 1)-pyridinium] dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(3-hy-
droxymethylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(2,4-di-
methylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(3,4-di-
methylpyridinium) dichloride; 
N,N'-{ 2,2'-[ oxybis(2, 1-ethandiyloxy )]bis-ethyl }-bis(3,5-di-
methylpyridinium) dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(2-methylpyridinium) 
dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3-methylpyridinium) 
dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-( 4-methylpyridinium) 
dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3,4-dimethylpyri-
dinium) dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(3,5-dimethylpyri-
dinium) dichloride; 
N,N'-(5, 7 -dodecadiyn-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydroiso-
quinolinium) dichloride; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-(3-methyl-pyri-
dinium) dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-( 4-methyl-pyri-
dinium) dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-( 5,6, 7,8-tetrahy-
droisoquiolinium) dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-(3,4-dimethyl-
pyridinium) dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-(3,5-dimethyl-
pyridiniuim) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-(3-meth-
ylpyridinium) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-( 4-meth-
ylpyridinium) dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(1-propyn-3-yl) ]-bis-(3,4-dim-
ethylpyridinium) dibromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as well as all 
combinations of diastereomers and enantiomers, including 
racemic mixtures. The compounds can be separated into 
substantially optically pure compounds. 
Pain from nervous system disorders of central and/or 
peripheral origin, which may be treated according to the 
method of the present invention and includes any disorders 
14 
involving pain including those types of pain referred to as 
nociceptive, neuropathic (chemical, viral or disease-in-
duced), inflammatory (arthritis, irritable bowel disease, 
Crohn's) as well as acute, chronic, cancer-related, and 
5 surgical, as well as pain resulting from any and all injuries, 
diseases or toxin induced injuries of the central or peripheral 
nervous systems including pain accompanying stroke, mul-
tiple sclerosis, parkinson's disease and pain from peripheral 
neuropathy as a result of diabetes, AIDs, chemotherapeutic 
10 drugs, and/or alcohol. 
Pain from cancer which may have its origin at any 
peripheral or central site and be caused by tumor invasion of 
bone, tissue or nerve. In another embodiment, the present 
invention is directed to a method for treating and/or pre-
15 venting neuropathy resulting from a medication which 
causes neuropathic pain as a side effect. For example, the 
compounds of the present invention may be used to treat 
and/or prevent pain associated with chemotherapy drugs 
such as vincristine. This is a very serious clinical condition 
20 associated with anticancer drugs. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/or treating inflam-
matory pain disorders comprising administering to a mam-
malian subject in need thereof a therapeutically effective 
25 amount of a compound of Formula (I). 
Inflammatory pain disorders which may be treated 
according to the method of the present invention include 
ankylosing spondylitis, benign prostatic hyperplasia, chole-
cystitis, ulcerative colitis, Crohn's disease, diabetes melli-
30 tus, gastritis, glomerulonephritis, irritable bowel syndrome, 
multiple sclerosis, osteoarthritis, pancreatitis, polymyositis, 
psoriasis and rheumatoid arthritis. 
The compounds of the present invention can be delivered 
to a mammalian organism, including a human, directly or in 
35 pharmaceutical compositions along with suitable carriers or 
excipients, as is well known in the art. For example, a 
pharmaceutical composition of the invention may include a 
conventional additive, such as a stabilizer, buffer, salt, 
preservative, filler, flavor enancer and the like, as known to 
40 those skilled in the art. Exemplary buffers include phos-
phates, carbonates, citrates and the like. Exemplary preser-
vatives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter-
mined by routine experimentation, as can the most effective 
45 and convenient route of administration and the most appro-
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington's Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
50 include oral, rectal, transmucosal, nasal, or intestinal admin-
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as well as intrath-
ecal, direct intraventricular, intravenous, intraperitoneal, 
intranasal, or intraocular injections. In addition, the agent or 
55 composition thereof may be administered sublingually or via 
a spray, including a sublingual tablet or a sublingual spray. 
The agent or composition thereof may be administered in a 
local rather than a systemic manner. For example, a suitable 
agent can be delivered via injection or in a targeted drug 
60 delivery system, such as a depot or sustained release for-
mulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods well-known in 
the art, such as by conventional mixing, dissolving, granu-
65 lating, dragee-making, levigating, emulsifying, encapsulat-
ing, entrapping, or lyophilizing processes. As noted above, 
the compositions of the present invention can include one or 
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more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
16 
Proper formulation is dependent upon the route of admin-
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in 
physiologically compatible buffers such as Hanks' solution, 
Ringer's solution, or physiological saline buffer. For trans-
mucosal or nasal administration, penetrants appropriate to 
the barrier to be permeated are used in the formulation. Such 
penetrants are generally known in the art. In a preferred 
embodiment of the present invention, the present com-
pounds are prepared in a formulation intended for oral 
administration. For oral administration, the compounds can 
15 
be formulated readily by combining the active compounds 
with pharmaceutically acceptable carriers well known in the 
art. Such carriers enable the compounds of the invention to 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently deliv-
ered in the form of an aerosol spray presentation from 
pressurized packs or a nebulizer, with the use of a suitable 
propellant, e.g., dichlorodifluoromethane, trichlorofluo-
romethane, dichlorotetrafluoroethane, carbon dioxide, or 
any other suitable gas. In the case of a pressurized aerosol, 
the appropriate dosage unit may be determined by providing 
a valve to deliver a metered amount. Capsules and cartridges 
10 of, for example, gelatin, for use in an inhaler or insuf!Iator 
may be formulated. These typically contain a powder mix of 
the compound and a suitable powder base such as lactose or 
starch. 
be formulated as tablets, pills, dragees, capsules, liquids, 
gels, syrups, slurries, suspensions and the like, for oral 20 
ingestion by a subject. The compounds may also be formu-
lated in rectal compositions such as suppositories or reten-
tion enemas, e.g., containing conventional suppository bases 
such as cocoa butter or other glycerides. 
Pharmaceutical preparations for oral use can be obtained 25 
as solid excipients, optionally grinding a resulting mixture, 
and processing the mixture of granules, after adding suitable 
auxiliaries, if desired, to obtain tablets or dragee cores. 
Suitable excipients are, in particular, fillers such as sugars, 
including lactose, sucrose, marmitol, or sorbitol; cellulose 30 
preparations such as, for example, maize starch, wheat 
starch, rice starch, potato starch, gelatin, gum tragacanth, 
methyl cellulose, hydroxypropylmethyl-cellulose, sodium 
carboxymethylcellulose, and/or polyvinylpyrrolidone 
(PVP). If desired, disintegrating agents may be added, such 35 
as the cross-linked polyvinyl pyrrolidone, agar, or alginic 
acid or a salt thereof such as sodium alginate. Also, wetting 
agents such as sodium dodecyl sulfate may be included. 
Dragee cores are provided with suitable coatings. For this 
purpose, concentrated sugar solutions may be used, which 40 
may optionally contain gum arabic, talc, polyvinyl pyrroli-
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identification or to characterize 45 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-fit capsules can contain the 50 
active ingredients in admixture with filler such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap-
sules, the active compounds may be dissolved or suspended 
in suitable liquids, such as fatty oils, liquid paraffin, or liquid 55 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dos-
ages suitable for such administration. 
Compositions formulated for parenteral administration by 
injection, e.g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The 
compositions may take such forms as suspensions, solu-
tions, or emulsions in oily or aqueous vehicles, and may 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Formulations for parenteral admin-
istration include aqueous solutions or other compositions in 
water-soluble form. 
Suspensions of the active compounds may also be pre-
pared as appropriate oily injection suspensions. Suitable 
lipophilic solvents or vehicles include fatty oils such as 
sesame oil and synthetic fatty acid esters, such as ethyl 
oleate or triglycerides, or liposomes. Aqueous injection 
suspensions may contain substances that increase the vis-
cosity of the suspension, such as sodium carboxymethyl 
cellulose, sorbitol, or dextran. Optionally, the suspension 
may also contain suitable stabilizers or agents that increase 
the solubility of the compounds to allow for the preparation 
of highly concentrated solutions. Alternatively, the active 
ingredient may be in powder form for constitution with a 
suitable vehicle, e.g., sterile pyrogen-free water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu-
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated with suitable poly-
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aque-
ous phase. The co-solvent system may be the VPD co-
solvent system. VPD is a solution of3% w/v benzyl alcohol, 
8% w/v of the nonpolar surfactant polysorbate 80, and 65% 
w/v polyethylene glycol 300, made up to volume in absolute 
ethanol. The VPD co-solvent system (VPD:5W) consists of 
VPD diluted 1: 1 with a 5% dextrose in water solution. This 
co-solvent system is effective in dissolving hydrophobic 
compounds and produces low toxicity upon systemic admin-
istration. Naturally, the proportions of a co-solvent system In one embodiment, the compounds of the present inven-
tion can be administered transdermally, such as through a 
skin patch, or topically. In one aspect, the transdermal or 
topical formulations of the present invention can addition-
ally comprise one or multiple penetration enhancers or other 
effectors, including agents that enhance migration of the 
delivered compound. Transdermal or topical administration 
could be preferred, for example, in situations in which 
location specific delivery is desired. 
60 may be varied considerably without destroying its solubility 
and toxicity characteristics. Furthermore, the identity of the 
co-solvent components may be varied. For example, other 
low-toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
65 be varied, other biocompatible polymers may replace poly-
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sug-
ars or polysaccharides may substitute for dextrose. 
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Alternatively, other delivery systems for hydrophobic 
molecules may be employed. Liposomes and emulsions are 
well known examples of delivery vehicles or carriers for 
hydrophobic drugs. Liposomal delivery systems are dis-
cussed above in the context of gene-delivery systems. Cer- 5 
tain organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus-
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
10 
of the composition to be administered. Various sustained-
release materials are established and available to those of 
skill in the art. Sustained-release capsules may, depending 
on their chemical nature, release the compounds for a few 
weeks up to over 100 days. Depending on the chemical 
nature and the biological stability of the therapeutic reagent, 15 
additional strategies for stabilization may be employed. 
For any composition used in the present methods of 
treatment, a therapeutically effective dose can be estimated 
initially using a variety of techniques well known in the art. 
For example, in a cell culture assay, a dose can be formu- 20 
lated in animal models to achieve a circulating concentration 
range that includes the IC50 as determined in cell culture. 
Dosage ranges appropriate for human subjects can be deter-
mined, for example, using data obtained from cell culture 
assays and other animal studies. A therapeutically effective 25 
dose of an agent refers to that amount of the agent that 
results in amelioration of symptoms or a prolongation of 
survival in a subject. Toxicity and therapeutic efficacy of 
such molecules can be determined by standard pharmaceu-
tical procedures in cell cultures or experimental animals, 30 
e.g., by determining the LD50 (the dose lethal to 50% of the 
population) and the ED 5 0 (the dose therapeutically effective 
in 50% of the population). The dose ratio of toxic to 
therapeutic effects is the therapeutic index, which can be 
expressed as the ratio LD50/ED50 . Agents that exhibit high 35 
therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating 
concentrations that includes the ED50 with little or no 
toxicity. Dosages may vary within this range depending 
upon the dosage form employed and the route of adminis- 40 
tration utilized. The exact formulation, route of administra-
tion, and dosage should be chosen, according to methods 
known in the art, in view of the specifics of a subject's 
condition. 
The amount of agent or composition administered will, of 45 
course, be dependent on a variety of factors, including the 
sex, age, and weight of the subject being treated, the severity 
of the affliction, the manner of administration, and the 
judgment of the prescribing physician. 
18 
plary of the invention. The present invention is not limited 
in scope by the exemplified embodiments, which are 
intended as illustrations of single aspects of the invention 
only. Any methods that are functionally equivalent are 
within the scope of the invention. Various modifications of 
the invention in addition to those described herein will 
become apparent to those skilled in the art from the fore-
going description. Such modifications fall within the scope 
of the appended claims. 
Example 1 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-[3-(2'-S-1-methyl-pyrrolidin-2-
yl)-pyridinium] dibromide 
Br 
-
The present compositions may, if desired, be presented in 50 
a pack or dispenser device containing one or more unit 
dosage forms containing the active ingredient. Such a pack 
cis-cis-1,12-Dibromo-dodeca-5,7-diene (1 mmol) was 
added to a solution ofS-nicotine (3 mmol) in acetonitrile and 
55 the solution refluxed for 24 hours. The acetonitrile was 
or device may, for example, comprise metal or plastic foil, 
such as a blister pack. The pack or dispenser device may be 
accompanied by instructions for administration. Composi-
tions comprising a compound of the invention formulated in 
a compatible pharmaceutical carrier may also be prepared, 
placed in an appropriate container, and labeled for treatment 
of an indicated condition. 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no S-nicotine left in the aqueous 
These and other embodiments of the present invention 60 
will readily occur to those of ordinary skill in the art in view 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (70% ). 1 HNMR (300 
MHZ, D20, ppm) 8.60 (s, 2H), 8.59 (d, 2H), 8.32 (d, 1=8.4, 
of the disclosure herein, and are specifically contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
following examples, which are intended to be purely exem-
2H), 7.88 (t, 1=5.7, 2H), 6.12-6.20 (m, 2H), 5.30-5.40 (m, 
2H), 4.43 (t, 1=7.2, 4H), 3.39 (t, 1=8.4, 2H), 3.01-3.06 (m, 
2H), 2.16-2.34 (m, 4H), 2.01-2.09 (m, 10H), 1.64-1.88 (m, 
65 10H), 1.25 (p, 1=7.5, 4H). 13CNMR, 144.67, 143.35, 132.20, 
128.45, 124.12, 67.65, 62.05, 56.65, 39.41, 33.76, 30.32, 
26.34, 25.47, 22.36. 
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Example 2 
20 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (76%). 1HNMR (300 MHZ, D20, 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(2-methyl-pyridinium) dibro-
mide 5 ppm) 8.50 (s, 2H), 8.44 (d, 1=6.3, 2H), 8.16 (d, 1=7.8, 2H), 
7.74 (dd, 1=7.8, 1=6.3, 2H), 6.15-6.18 (m, 2H), 5.38-5.38 
(m, 2H), 4.38 (t, 1=5.7, 4H), 2.35 (s, 6H), 2.06 (q, 1=7.5, 
4H), 1.83 (p, 1=7.5, 4H), 1.25 (p, 1=7.5, 4H). 13CNMR, 
145.99, 143.71, 141.30, 139.95, 132.19, 127.46, 124.06, 
Br 10 61.69, 30.27, 26.35, 25.44, 17.93. 
Br 
e 
2Br 
--
15 
20 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 2-picoline (3 mmol) in acetonitrile and the 25 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 30 
yield the pure product. (76%). 1HNMR (300 MHz, D20, 
ppm) 8.52 (dd, 1=6.3, 2H), 8.17 (dt, 1=7.8, 1=1.5, 2H), 7.72 
(d, 1=7.8, 2H), 7.64 (t, 1=6.3, 2H), 6.18-6.23 (m, 2H), 
5.33-5.41 (m, 2H), 4.37 (t, 1=7.1, 4H), 2.66 (s, 6H), 2.09 (q, 
1=7.5, 4H), 1.72-1.82 (m, 4H), 1.36 (p, 1=7.5, 4H). 35 
13CNMR, 155.26, 145.01, 144.73, 132.25, 130.23, 125.64, 
124.15, 58.06, 29.10, 26.38, 25.61, 19.73. 
Example 3 
Br 
Example 4 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1 ,12-diyl)-bis-( 4-methyl-pyridinium) dibro-
mide 
Br 
# 
0 
N 
--
-eN 
e 
2Br 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 4-picoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(3-methyl-pyridinium) dibro-
mide 
40 in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
Br 
45 ppm), 8.45 (d, 1=6.9, 4H), 7.68 (d, 1=6.9, 4H), 6.14-6.19 (m, 
2H), 5.31-5.39 (m, 2H), 4.35 (t, 1=7.2, 4H), 2.47 (s, 6H), 
2.07 (q, 1=7.2, 4H), 1.83 (p, 1=7.5, 4H), 1.25 (p, 1=7.5, 4H). 
Br # 
u 
N 
e 
2Br 
50 
;=!_55 
Nu 
60 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 3-picoline (3 mmol) in acetonitrile and the 65 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
Br 
Example 5 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydro-quino-
linium) dibromide 
Br 
# 
c9 
N 
--
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-continued 
e 
2Br 10 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 5,6,7,8-tetrahydro-quinoline (3 mmol) in 
acetonitrile and the solution refluxed for 24 hours. The 15 
acetonitrile was removed in vacuum and the resulting resi-
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no quinoline 
left in the aqueous layer. The resulting aqueous solution of 
the product was lyophilized to yield the pure product. (75%). 20 
1HNMR (300 MHz, D20, ppm) 8.35 (d, 1=6.3, 2H), 7.97 (d, 
1-8.1, 2H), 7.52 (dd, 1=8.1, 1=6.3, 2H), 6.16-6.22 (m, 2H), 
5.32-5.42 (m, 2H), 4.30 (t, 1=7.8, 4H), 2.92 (t, 1=6.2, 4H), 
2.79 (t, 1=6.2, 4H), 2.09 (q, 1-7.2, 4H), 1.60-1.83 (m, 12H), 
1.36 (p, 1=7.5S 4H). 
Example 6 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(5,6, 7 ,8-tetrahydro-isoquino-
linium) dibromide 
25 
30 
22 
(m, 8H), 1.22 (p, 1=7.2, 4H). CNMR158.82, 143.10, 139.60, 
138.96, 132.28, 127.92, 124.09, 60.82, 49.13, 30.07, 29.35, 
26.32, 26.20, 25.43, 21.01. 
Example 7 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(2,4-dimethyl-pyridinium) 
dibromide 
Br 
J) -
--O~V 
e 
2Br 
Br 
Br c9 
N 
-
e 
2Br 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
I t . f 5 6 7 8 t t h d · · 1· (3 I) · solution of 2, 4-lutidine {3 mmol) in acetonitrile and the 
so u Jon ° ' ' ' -era y ro-Jsoqumo me mmo m 55 solution refluxed for 24 hours. The acetonitrile was removed 
acetonitrile and the solution refluxed for 24 hours. The 
acetonitrile was removed in vacuum and the resulting resi-
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no isoquino-
60 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2, 4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, line left in the aqueous layer. The resulting aqueous solution 
of the product was lyophilized to yield the pure product. 
(75%). 1HNMR (300 MHz, D20, ppm) 8.30 (s, 2H), 8.19 (d, 
1=6.6, 2H), 7.50 (d, 1=6.3, 2H), 6.09-6.16 (m, 2H), 5.28-5.36 
(m, 2H), 4.27 (t, 1=7.2, 4H), 2.29-2.82 (br, 4H), 2.67-2.74 
(br, 4H), 2.02 (q, 1=7.2, 4H), 1.81 (p, 1=7.2, 4H), 1.62-1.69 
ppm) 8.31 (d, 1=6.3, 2H), 7.53 (s, 2H), 7.46 (d, 1=6.9, 2H), 
6.16-6.22 (m, 2H), 5.32-5.40 (m, 2H), 4.28 (t, 1=8.1, 4H), 
2.58 (s, 3H), 2.38 (s, 3H), 2.07 (q, 1=7.2, 4H), 1.74 (p, 1=7.5, 
65 4H), 1.33 (p, 1=7.5, 4H). CNMR, 159.20, 153.87, 143.69, 
132.32, 130.44, 126.34, 124.18, 57.19, 29.10, 26.41, 25.63, 
21.19, 19.46. 
US 9,499,518 B2 
Br 
23 
Example 8 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(3,4-dimethyl-pyridinium) 
dibromide 
Br 
-
10 
15 
Nrr-
~ 20 
0 
2Br 
24 
-continued u 
N 
-
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 3, 5-lutidine (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3, 5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
ppm) 8.29 (s, 4H), 7.99 (s, 2H), 6.12-6.18 (m, 2H), 5.30-5.38 
(m, 2H), 4.31 (t, 1=7.5, 4H), 2.30 (s, 6H), 2.05 (q, 1=7.2, 
4H), 1.81 (p, 1=7.5, 4H), 1.24 (p, 1-7.5, 4H). CNMR, 146.56, 
cis-cis-1,12-Dibromo-dodeca-5,7-diene was added to a 
solution of 3, 4-lutidine (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
25 140.96, 139.11, 132.28, 124.09, 61.49, 30.21, 26.34, 25.43, 
17.73. 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 30 
with ether until no 3, 4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
ppm) 8.34 (s, lH), 8.29 (d, 1=6.3, lH), 7.60 (d, 1=6.3, lH), 
-Br Br 
6.13-6.18 (m, 2H), 5.30-5.38 (m, 2H), 4.31 (t, 1=7.2, 4H), 50 
2.37 (s, 3H), 2.25 (s, 3H), 2.05 (q, 1=7.2, 4H), 1.81 (p, 1=7.5, 
4H), 1.24 (p, 1=7.5, 4H). CNMR, 158.66, 142.37, 140.71, 
138.65, 132.25, 128.23, 124.07, 60.80, 30.11, 26.31, 25.42, 
19.69, 16.34. 
Example 10 
Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl) ]-bis-[3-(2'-S-1-methyl-pyrrolidin-2-yl)-
pyridinium] dibromide 
2Br0 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of S-nicotine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
Example 9 
Synthesis of Compound cis-cis-N,N'-(dodeca-5,7-
diene-1, 12-diyl)-bis-(3,5-dimethyl-pyridinium) 
dibromide 
55 ether and water. The aqueous layer was washed extensively 
with ether until no S-nicotine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
Br 
Br 
60 ppm) 8.57-8.59 (m, 4H), 8.35 (d, 1=8.1, 2H), 7.88 (dd, 1=7.8, 
1=6.6, 2H), 7.01 (s, 4H), 4.45 (t, 1=7.5, 4H), 3.40 (t, 2H), 
3.04-3.10 (m, 2H), 2.49 (t, 1=7.5, 4H), 2.30-2.40 (m, 2H), 
2.18-2.29 (m, 2H), 2.03 (s, 6H), 1.80-1.90 (m, 8H), 1.40-
65 1.55 (m, 4H). CNMR, 144.65, 143.48, 143.30, 139.76, 
128.74, 128.42, 67.61, 61.99, 56.62, 39.37, 33.96, 33.73, 
30.17, 27.28, 22.33. 
US 9,499,518 B2 
Br 
25 
Example 11 
Synthesis of Compound N,N'[1,4-phenylenedi-( 4-
butanyl)]-bis-(2-methylpyridinium) dibromide 
--Br 
2Br0 
1,4-Bis-( 4-bromo-butyl)-benzene was added to a solution 
of 2-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
ppm) 8.49 (dd, 1=6.0, 1.2, 2H), 8.17 (dt, 1=8.1, 1=1.5, 2H), 
7.70 (d, 1=8.1, 2H), 7.65 (dt, 1=8.1, 1=1.2, 2H), 7.04 (s, 4H), 
4.37 (t, 1=7.2, 4H), 2.62 (s, 6H), 2.51 (t, 1=7.2, 4H), 1.77 (p, 
1=7.8, 4H), 1.57 (p, 1=7.8, 4H). CNMR. 145.05, 144.73, 
139.79, 130.24, 128.78, 125.64, 58.02, 34.11, 29.01, 27.49, 
19.70. 
Br 
Example 12 
Synthesis of Compound N,N'[1,4-phenylenedi-( 4-
butanyl)]-bis-(3-methylpyridinium) dibromide 
2Br0 
--Br 
26 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of 3-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
5 ether and water. The aqueous layer was washed extensively 
with ether until no 3-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
ppm) 8.45 (s, 2H), 8.40 (d, 1=6.6, 2H), 8.16 (d, 1=8.1, 2H), 
10 
7.72 (dd, 1=8.1, 1=6.0, 2H), 7.00 (s, 4H), 4.37 (t, 1=7.5, 4H), 
2.47 (t, 1=7.5, 4H), 2.34 (s, 6H), 1.82 (p, 1=7.5, 4H), 1.46 (p, 
1=7.5, 4H). CNMR. 146.02, 143.68, 141.68, 139.96, 139.79, 
128.75, 127.46, 61.69, 34.04, 30.14, 27.28, 17.90. 
20 
25 
30 
Br 
Example 13 
Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl)]-bis-(4-methylpyridinium) dibromide 
--Br 
» ~ I# 
2Br0 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of 4-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
35 vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 4-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
40 ppm) 8.38 (d, 1-6.9, 4H), 7.64 (d, 1=6.9, 4H), 6.98 (s, 4H), 
4.33 (t, 1=7.2, 4H), 2.46 (t, 1=7.2, 4H), 2.44 (s, 6H), 1.81 (p, 
1=7.5, 4H), 1.45 (p, 1=7.5, 4H). CNMR. 159.99, 143.04, 
139.79, 128.74, 128.65, 60.99, 34.02, 30.03, 27.26, 21.50. 
45 
50 
Example 14 
Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl)]-bis-(3-ethylpyridinium) dibromide 
~~ v 
2Br0 
US 9,499,518 B2 
27 28 
1,4-Bis-( 4-bromo-butyl)-benzene was added to a solution -continued 
of 3-ethylpyridine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 5 
with ether until no 3-ethylpyridine left in the aqueous layer. 
The resulting aqueous solution of the groduct was 
lyophilized to yield the pure product. (75%). HNMR (300 
MHZ, D20, ppm) 8.45 (s, 2H), 8.41 (d, 1-6.0, 2H), 8.19 (d, 
1=8.4, 2H), 7.73 (dd, 1=8.1, 1=6.0, 2H), 6.97 (s, 4H), 4.37 (t, 
1=7.2, 4H), 2.66 (q, 7.8, 2H), 2.49 (t, 1-7.2, 1.83 (p, 1=7.5, 10 
4H), 1.45 (p, 1-1.5, 4H), 1.09 (t, 1=7.8, 6H). CNMR. 145.61, 
145.08, 143.09, 141.51, 139.78, 128.75, 127.68, 61.70, 
34.01, 30.13, 27.24, 25.70, 13.92. 
N~ v 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of tetrahydroquinoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
Br 
Example 15 
Synthesis of Compound N,N'[1,4-phenylenedi-( 4-
butanyl)]-bis-(5,6,7,8-tetrahydroquinolinium) dibro-
mide 
15 ether and water. The aqueous layer was washed extensively 
with ether until no tetrahydroquinoline left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1HNMR (300 
MHZ, D20, ppm) 8.30 (d, 1=6.3, 2H), 7.95 (d, 1=7.8, 2H), 
20 7.49 (dd, 1=8.1, 1=6.3, 2H), 7.02 (s, 4H), 4.28 (t, 7.5, 4H), 
2.83 (t, 1=7.5, 4H), 2.77 (t, 1=7.5, 4H), 2.49 (t, 1=7.5, 4H), 
1.66-1.80 (m, 8H), 1.35-1.63 (m, 8H). 
Example 16 
Br- 25 Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl)]-bis-(5,6,7,8-tetrahydroisoquinolinium) 
dibromide 
Br 
Br 
40 
Br-
~~ 
VJ 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of tetrahydroisoquinoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
45 ether and water. The aqueous layer was washed extensively 
with ether until no tetrahydroisoquinoline left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1HNMR (300 
MHZ, D20, ppm) 8.21 (s, 2H), 8.13 (d, 1=6.3, 2H), 7.46 (d, 
50 
1=6.3, 2H), 6.96 (s, 4H), 4.25 (t, 1=7.2, 4H), 2.2.78-2.84 (br, 
4H), 2.63-2.70 (br, 4H), 2.44 (t, 1=7.2, 4H), 1.78 (p, 1=7.5, 
4H), 1.64-1.70 (m, 8H), 1.42 (p, 1=7.5, 4H). CNMR, 158.77, 
143.03, 139.78, 139.56, 138.88, 128.72, 127.84, 60.79, 
49.11, 34.01, 29.91, 29.31, 27.16, 26.16, 20.99. 
55 Example 17 
Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl)]-bis-[3-(3-hydroxy-propyl)-pyridinium] 
dibromide 
Br-
US 9,499,518 B2 
~~ 
HO) v 
29 
-continued 
1,4-Bis-( 4-bromo-butyl)-benzene was added to a solution 10 
of {3-hydroxy-propyl)-pyridine (3 mmol) in acetonitrile and 
the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no (3-hydroxy-propyl)-pyridine 15 
left in the aqueous layer. The resulting aqueous solution of 
the product was lyophilized to yield the pure product. (75%). 
1HNMR (300 MHZ, D 20, ppm) 8.49 (s, 2H), 8.43 (d, 1=6.0, 
2H), 8.22 (d, 1=8.1, 2H), 7.75 (dd, 1=7.8, 1=6.0, 2H), 6.98 
(s, 4H), 4.38 (t, 1=7.2, 4H), 3.45 (t, 1=6.6, 4H), 2.72 (t, 1=7.8, 20 
4H), 2.46 (t, 1=7.5, 4H), 1.83 (p, 1-7.5, 4H), 1.70-1.75)m, 
4H), 1.44 (p, 1-7.5, 4H). CNMR, 145.53, 143.51, 141.78, 
139.78, 128.75, 127.78, 61.75, 60.67, 34.01, 32.17, 30.13, 
28.81, 27.24. 
30 
-continued 
~~ 
~ 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of 3,4-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
Example 18 
Synthesis of Compound N,N'[1,4-phenylenedi-( 4-
butanyl)]-bis-(2,4-dimethylpyridinium) dibromide 
25 ether and water. The aqueous layer was washed extensively 
with ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D 20, 
ppm) 8.25 (s, 2H), 8.22 (d, 1-6.0, 2H), 7.55 (d, 1=6.0, 2H), 
Br Br--
30 6.96 (s, 4H), 4.27 (t, 1=7.2, 4H), 2.45 (t, 1=7.2, 4H), 2.34 (s, 
6H), 2.21 (s, 6H), 1.79 (p, 1=7.5, 4H), 1.42 (p, 1=7.5, 4H). 
CNMR, 158.64, 142.28, 140.66, 139.78, 138.61, 128.72, 
128.18, 34.02, 29.94, 27.20, 19.67, 16.29. 
35 
D ~ I# 
2Br
6 40 
1,4-Bis-( 4-bromo-butyl)-benzene was added to a solution 
of 2,4-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 45 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D 20, 50 
ppm) 8.27 (d, 1=6.6, 2H), 7.50 (s, 2H), 7.45 (d, 1=6.6, 2H), 
7.02 (s, 4H), 4.28 (t, 1=7.2, 4H), 2.52 (s, 6H), 2.48 (t, 1=7.2, 
4H), 2.38 (s, 6H), 2.20 (s, 3H), 1.79 (p, 1=7.5, 4H), 1.42 (p, 
1=7.5, 4H). 
55 
Example 19 
Example 20 
Synthesis of Compound N,N'[1,4-phenylenedi-(4-
butanyl)]-bis-(3,5-dimethylpyridinium) dibromide 
[ZZ 1 82] 
1,4-Bis-(4-bromo-butyl)-benzene was added to a solution 
of 3,5-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
Synthesis of Compound N,N'[1,4-phenylenedi-( 4-
butanyl)]-bis-(3,4-dimethylpyridinium) dibromide 
[ZZ 1 81] 60 ether and water. The aqueous layer was washed extensively 
with ether until no 3,5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1HNMR (300 MHZ, D20, 
Br Br -- 65 
ppm) 8.23 (s, 4H), 7.97 (s, 2H), 6.97 (s, 4H), 4.29 (t, 1=7.2, 
4H), 2.45 (t, 1=7.2, 4H), 2.27 (s, 12H), 1.81 (p, 1=7.5, 4H), 
1.45 (p, 1=7.5, CNMR, 146.50, 140.89, 139.79, 139.04, 
128.74, 63.46, 34.04, 30.03, 27.22, 17.70. 
US 9,499,518 B2 
31 
Example 21 
Synthesis of Compound 5-[2-(5-hydroxy-pent-1-
ynyl)-phenyl]-pent-4-yn-1-ol 
CC ~ -- # Br 
OH 
OH 
1,2-Dibromobenzene (10.94 g, 46.37 mmol), 4-pentyn-1-
10 
15 
ol (9.36 g, 111.30 mmol), and bis(triphenylphosphine)pal-
ladium(II) dichloride (650 mg, 0.93 mmol) was stirred in 
triethylamine (150 mL) under nitrogen for 5 min. Copper(!) 
iodide (88 mg, 0.46 mmol) was added and the mixture was 20 
stirred for 4 hrs at 85° C. for 6 days. The mixture was cooled 
32 
ppm; 13C NMR (75 MHz, CDC13 ) o 18.6, 31.8, 32.7, 80.7, 
91.8, 125.9, 127.6, 131.9 ppm. 
Example 23 
Synthesis of Compound 1,2-bis-[5-(2-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
Br 
~ --# 
Br 
to room temperature and filtered through a celite pad, rinsed 
with ethylacetate. The combined filtrate was evaporated to 
dryness under reduced pressure. The resulting residue was 
purified by colunm chromatography ( chloroform:methanol 25 
30:1) to afford 5.33 g of the title compound. Yield: 47%. 1H 
NMR (300 MHZ, D20, ppm) o 1.85 (m, 4H), 2.58 (t, 1=6.6 
Hz, 4H), 3.82 (t, 1=6.0 Hz, 4H), 7.18 (m, 2H), 7.36 (m, 2H) 
ppm; 13C NMR (75 MHz, CDC13 ) o 16.3, 31.4, 62.4, 80.2, 
93.3, 126.0, 127.4, 131.8 ppm. 
Example 22 
Synthesis of Compound 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
30 (264 mg, 0.72 mmol) and 2-picoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 327 
1 ,2-bis-(5-bromo-pent-1-ynyl)-benzene 
OH 
35 mg of the title compound. Yield: 82%. 1 H NMR (300 MHz, 
CD30D) o2.35 (m, 4H), 2.81 (t, 1=6.6 Hz, 4H), 3.02 (s, 6H), 
4.91 (t, 1=7.5 Hz, 4H)," 7.27-7.50 (m, 4H), 7.92-8.15 (m, 
4H), 8.45 (t, 1=7.8 Hz, 2H), 9.11 (d, 1=6.3 Hz, 2H) ppm; 13C 
NMR (75 MHz, CD3 0D) o17.6, 21.1, 30.1, 58.2, 81.9, 92.9, 
40 126.4, 127.0, 129.2, 129.3, 131.5, 133.1, 146.4, 156.7 ppm. 
--
OH 
45 
Br 
50 
Br 
5-[2-( 5-Hydroxy-pent-1-yny I)-phenyl]-pent-4-yn-1-ol 
(2.40 g, 9.90 mmol) and carbon tetrabromide (8.21 g, 24.75 55 
mmol) were dissolved in dry methylene chloride (30 mL) 
and cooled to oo C. Triphenyl phosphine (6.82 g, 25.99 
mmol) in methylene chloride (15 mL) was added dropwise 
and the mixture was stirred for 1 h at oo C. The mixture was 
poured into hexanes (200 mL) and then filtered through a 60 
short silica gel column, washed with ethylacetate/hexanes 
(1/4). The combined organic solvents were evaporated to 
dryness under reduced pressure. The resulting residue was 
purified by colunm chromatography (hexanes:ethylacetate 
30:1) to afford 2.48 g of the title compound. Yield: 68%. 1H 65 
NMR (300 MHz, CDC13 ) o2.16 (m, 4H), 2.68 (t, 1=6.6 Hz, 
4H), 3.65 (dt, 1=6.6, 0.6 Hz, 4H), 7.20 (m, 2H), 7.38 (m, 2H) 
Example 24 
Synthesis of Compound 1,2-bis-[5-(3-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
Br 
--
Br 
US 9,499,518 B2 
33 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(270 mg, 0.73 mmol) and 3-picoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 5 
mLx3). Water was removed by lyophilization to afford 350 
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz, 
CD3 0D) o2.45 (m, 4H), 2.56 (s, 6H) 2.78 (t, 1=6.6 Hz, 4H), 
4.95 (t, 1=7.2 Hz, 4H), 7.22-7.42 (m, 4H), 8.05 (dd, 1=8.1, 
6.0 Hz, 2H), 8.39 (d, 1=7.8 Hz, 2H), 9.10 (d, 1=6.0 Hz, 2H), 10 
9.19 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o17.6, 18.9, 
31.2, 61.9, 81.6, 92.8, 126.4, 128.7, 129.0, 132.9, 140.9, 
143.1, 145.6, 147.3 ppm. 
34 
-continued 
~ 
~ b-
# 
2Br8 
~ y-
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
Example 25 
Synthesis of Compound 1,2-bis-[5-( 4-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
15 (268 mg, 0.73 mmol) and 2,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 343 
Br 
--
Br 
~ 
~ ) 
# 
2Br8 
~ ) 
20 mg of the title compound. Yield: 81%. 1 H NMR (300 MHz, 
CD30D) o 2.34 (m, 4H), 2.52 (s, 3H), 2.84 (t, 1-6.6 Hz, 4H), 
2.97 (s, 3H), 4.87 (t, 1=7.5 Hz, 4H), 7.27-7.45 (m, 4H), 7.80 
(d, 1=6.3 Hz, 2H), 7.87 (s, 2H), 8.99 (d, 1=6.3 Hz, 2H) ppm; 
13C NMR (75 MHz, CD3 0D) o17.6, 20.9, 22.0, 30.1, 57.5, 
25 81.6, 93.0, 126.4, 127.6, 129.1, 131.7, 133.0, 145.5, 155.5, 
160.3 ppm. 
30 
35 
Example 27 
Synthesis of Compound 1,2-bis-[5-(3,4-dimethyl-
pyridinium)-pent-1-ynyl]-benzene dibromide [GZ 
581 B] 
Br 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(268 mg, 0.73 mmol) and 4-picoline (1 mL) was heated at 40 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 435 
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz, 45 
CD3 0D) o2.41 (m, 4H), 2.51 (s, 6H), 2.78 (t, 1=6.6 Hz, 4H), 
4.91 (t, 1=6.6 Hz, 4H), 7.30 (s, 4H), 7.92 (d, 1=6.3 Hz, 4H), 
9.05 (d, 1=6.3 Hz, 4H) ppm; 13C NMR (75 MHz, CD3 0D) 
Br 
--
0 17.5, 22.3, 31.0, 61.4, 81.5, 92.8, 126.4, 129.0, 129.8, 
132.9, 144.9, 161.1 ppm. 
Example 26 
Synthesis of Compound 1 ,2-bis-[5-(2,4-dimethyl-
pyridinium )-pent -1-yny !]-benzene dibromide 
Br 
--
Br 
50 
55 A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(276 mg, 0.75 mmol) and 3,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
60 mLx3). Water was removed by lyophilization to afford 355 
mg of the title compound. Yield: 81%. 1 H NMR (300 MHz, 
CD30D) o 2.37 (s, 3H), 2.40 (s, 3H), 2.44 (m, 4H), 2.79 (t, 
1=6.6 Hz, 4H), 4.88 (t, 1=6.6 Hz, 4H), 7.29 (s, 4H), 7.86 (d, 
1=6.3 Hz, 2H), 8.95 (d, 1=6.3 Hz, 2H), 9.06 (s, 2H), ppm; 
65 
13C NMR (75 MHz, CD3 0D) o17.3, 17.7, 20.4, 31.1, 61.2, 
81.3, 93.0, 126.5, 129.0, 129.4, 132.8, 139.5, 142.7, 144.3, 
159.8 ppm. 
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Example 28 
Synthesis of Compound 1 ,2-bis-[5-(3,5-dimethyl-
pyridinium)-pent-1-ynyl]-benzene dibromide [GZ 
581 A] 
Br 
-
Br 
10 
15 
36 
-continued 
~ B ~ j 
# 
2Br8 
~ 8 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(249 mg, 0.68 mmol) and quinoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
20 diethyl ether and then dissolved in water (30 mL), the 
aqueous solution was extracted with chloroform (20 mLx3). 
Water was removed by lyophilization to afford 317 mg of the 
title compound. Yield: 75%. 1H NMR (300 MHz, CD3 0D) 
e 25 
2Br 
o 2.42 (m, 4H), 2.78 (t, 1=6.6 Hz, 4H), 5.36 (t, 1=6.9 Hz, 
4H), 7.02-7.28 (m, 4H), 7.97 (t, 1=7.5 Hz, 2H), 8.07-8.40 
(m, 4H), 8.67 (d, 1=9.0 Hz, 2H), 9.15 (d, 1=8.4 Hz, 2H), 9.15 
(d, 1=8.4 Hz, 2H), 9.70 (d, 1=5.7 Hz, 2H) ppm; 13C NMR 
(75 MHz, CD3 0D) o 17.8, 29.8, 58.5, 81.6, 92.9, 119.7, 
123.2, 126.2, 129.0, 130.5, 131.3, 132.0, 132.7, 137.2, 
A 
r~ 30 139.0, 149.0, 150.6 ppm. 
35 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(280 mg, 0.76 mmol) and 3,5-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
40 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 363 
mg of the title compound. Yield: 82%. 1 H NMR (300 MHz, 
CD3 0D) o2.42 (m, 4H), 2.51 (s, 6H), 2.76 (t, 1-6.9 Hz, 4H), 
4.86 (t, 1=6.9 Hz, 4H), 7.30 (m, 4H), 8.13 (s, 2H), 8.95 (s, 45 
4H) ppm; 13C NMR (75 MHz, CD3 0D) o17.7, 18.7, 31.2, 
61.9, 81.6, 92.9, 126.6, 129.0, 132.8, 140.2, 142.9, 147.9 
ppm. 
Example 29 
Synthesis of Compound 
1 ,2-bis-[ 5-quinolinium-pent-1-ynyl)-benzene 
dibromide 
50 
55 
Example 30 
Synthesis of Compound 
1 ,2-bis-[ 5-isoquinolinium -pent-1-ynyl)-benzene 
dibromide [GZ 582 B] 
Br 
-
Br 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
Br 
-
60 (252 mg, 0.68 mmol) and isoquinoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethy!ether and then dissolved in water (30 mL), the 
aqueous solution was extracted with chloroform (20 mLx3). 
Water was removed by lyophilization to afford 319 mg of the 
Br 65 title compound. Yield: 74%. 1H NMR (300 MHz, CD3 0D) 
o 2.46 (m, 4H), 2.77 (t, 1=6.3 Hz, 4H), 5.01 (t, 1=6.6 Hz, 
4H), 6.91 (m, 2H), 7.04 (m, 2H), 7.90-8.50 (m, 10H), 8.78 
US 9,499,518 B2 
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(d, 1=6.9 Hz, 2H), 10.10 (s, 2H) ppm; 13C NMR (75 MHz, 
CD3 0D) o17.8, 30.8, 62.1, 81.3, 92.7, 125.7, 127.3, 128.1, 
128.5, 131.2, 131.4, 132.1, 132.2, 135.6, 137.9, 138.4, 150.8 
ppm. 
Example 31 
Synthesis of Compound 1,2-bis-[5-(2'-S-nicotinium-
pent-1-ynyl)]benzene dibromide 
Br 
-
Br 
10 
38 
-continued 
OH 
OH 
5-[2-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol 
(2.70 g, 11.14 mmol) was dissolved in ethanol (30 mL) and 
10% Pd!C (2.5% w/w) was added. The resulting mixture was 
15 hydrogenated on a Parr hydrogenation apparatus ( 45 psi) for 
4 hrs. The catalyst was removed by filtration through a Celite 
pad. The filter cake was rinsed with methanol, and the 
combined organic liquors were concentrated under reduced 
pressure. The crude product was purified by colunm chro-
20 matography ( chloroform:methanol 20:1) to afford 2.55 g of 
the title compound. Yield: 91%. 1H NMR (300 MHz, 
CDC13 ) o 1.38-1.67 (m, 12H), 2.60 (t, 1=7.8 Hz, 4H), 3.59 
(t, 1=6.6 Hz, 4H), 7.11 (m, 4H) ppm; 13C NMR (75 MHz, 
CDC13 ) o 26.0, 31.3, 32.6, 32.8, 62.6, 125.8, 129.1, 140.2 
25 ppm. 
Example 33 
Synthesis of Compound 
30 1 ,2-bis-[ 5-bromo-pentyl)-benzene 
OH 
35 
A mixture of 1,2-bis-(5-bromo-pent-1-ynyl)-benzene 
(330 mg, 0.90 mmol) and S-nicotine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
40 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with chloroform (20 mLx3). 
Water was removed by lyophilization to afford 340 mg of the 
title compound. Yield: 55%. 1H NMR (300 MHz, CD3 0D) 
OH 
-
Br 
o 2.00-2.82 (m, 16H), 2.55 (s, 6H), 2.90 (m, 2H), 3.55 (m, 
45 
2H), 4.17 (m, 2H), 4.95 (t, 1=6.9 Hz, 4H), 7.27 (m, 2H), 7.37 
(m, 2H), 8.17 (dd, 1=7.8, 6.3 Hz, 2H), 8.69 (d, 1=8.4 Hz, 
2H), 9.15 (d, 1=6.0 Hz, 2H), 9.40 (s, 2H) ppm; 13C NMR (75 
MHz, CD3 0D) o 17.5, 23.5, 30.9, 34.1, 40.3, 57.6, 62.4, 
68.7, 81.9, 92.7, 126.4, 129.1, 129.6, 133.0, 141.1, 145.8, 50 
146.0, 146.5 ppm. 
Br 
Example 32 
Synthesis of Compound 
5-[2-( 5-hydroxy-pentyl)-phenyl]-pentan-1-ol 
OH 
-
OH 
5-[2-(5-Hydroxy-penty])-phenyl]-pentan-1-ol (2.50 g, 
10.00 mmol) and carbon tetrabromide (8.29 g, 25.00 mmol) 
were dissolved in dry methylene chloride (30 mL) and 
55 cooled to oo C. Triphenylphosphine (6.88 g, 26.25 mmol) 
in methylene chloride (15 mL) was added dropwise and the 
mixture was stirred for 1 h at oo C. The mixture was poured 
into hexanes (200 mL) and then filtered through a short silica 
gel column, washed with ethylacetate/hexanes (3/4). The 
60 combined organic solvents were evaporated to dryness 
under reduced pressure. The resulting residue was purified 
by colunm chromatography (hexanes:ethylacetate30: 1) to 
afford 3.76 g of the title compound. Yield: 99%. 1H NMR 
(300 MHz, CDC13 ) 61.47-1.73 (m, 8H), 1.91 (m, 4H), 2.63 
65 (t, 1=7.8 Hz, 4H), 3.42 (t, 1=6.9 Hz, 4H), 7.15 (s, 4H) ppm; 
13C NMR (75 MHz, CDC13 ) o 28.5, 30.6, 32.7, 32.9, 34.0, 
126.0, 129.2, 139.9 ppm. 
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Example 34 
Synthesis of Compound 
1,2-bis-[5-(2-methyl-pyridinium)-pentyl]-benzene 
dibromide 
Br 
-
Br 
0 
9 N 
10 
15 
20 
25 
2Br
8 
30 
40 
-continued 
u 
2Bfl 
~ 
h~ 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (296 mg, 
0.79 mmol) and 3-picoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 382 mg of the title 
compound. Yield: 86%. 1H NMR (300 MHz, CD3 0D) o 
1.47 (m, 4H), 1.66 (m, 4H), 2.08 (m, 4H), 2.59 (s, 6H), 2.65 
(t, 1=7.5 Hz, 4H), 4.64 (t, 1=7.5 Hz, 4H), 7.01-7.19 (m, 4H), 
7.99 (d, 1=7.5, 6.0 Hz, 2H), 8.43 (dd, 1=8.1, 0.6 Hz, 2H), 
8.86 (d, 1=6.0 Hz, 2H), 8.96 (s, 2H) ppm; 13C NMR (75 
MHz, CD3 0D) o 18.7, 27.2, 32.0, 32.6, 33.5, 62.9, 127.1, 
128.7, 130.3, 141.0, 141.2, 143.1, 145.5, 147.2 ppm. 
Example 36 
Synthesis of Compound 
1 ,2-bis-[ 5-( 4-methyl-pyridinium)-pentyl]-benzene 
dibromide 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (280 mg, 
35 
0.74 mmol) and 2-picoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
Br 
was removed by lyophilization to afford 400 mg of the title 40 I 
compound. Yield: 95%. 1H NMR (300 MHz, CD30D) o 
~ 
# -
1.54 (m, 4H), 1.68 (m, 4H), 2.01 (m, 4H), 2.69 (t, 1=7.5 Hz, 
4H), 2.90 (s, 6H), 4.61 (t, 1=7.8 Hz, 4H), 7.02-7.19 (m, 4H), 
7.92 (t, 1=6.6 Hz, 2H), 8.00 (d, 1=7.8 Hz, 2H), 8.44 (dt, 
1=7.8, 1.2 Hz, 2H), 8.93 (dd, 1=6.3, 1.2 Hz, 2H) ppm; 13C 45 
NMR (75 MHz, CD3 0D) o20.8, 27.4, 31.2, 32.0, 33.4, 59.3, 
126.9, 127.0, 130.3, 131.5, 141.0, 146.3, 146.4, 156.6 ppm. 
Br 
Q 
Example 35 
Synthesis of Compound 
1,2-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene 
dibromide 
Br 
-
Br 
50 
55 
2Bfl 
() N 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (290 mg, 
0.77 mmol) and 4-picoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
60 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 387 mg of the title 
compound. Yield: 89%. 1H NMR (300 MHz, CD3 0D) o 
1.44 (m, 4H), 1.65 (m, 4H), 2.04 (m, 4H), 2.64 (t, 1=7 .5 Hz, 
4H), 2.68 (s, 6H), 4.58 (t, 1=7.5 Hz, 4H), 7.02-7.15 (m, 4H), 
65 7.92 (d, 1=6.3 Hz, 4H), 8.83 (dd, 1=5.1, 1.8 Hz, 4H) ppm; 
13C NMR (75 MHz, CD3 0D) o22.3, 27.0, 31.9, 32.3, 33.3, 
62.0, 127.0, 129.8, 130.2, 140.9, 144.7, 160.8 ppm. 
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Example 37 
Synthesis of Compound 1 ,2-bis-[5-(2,4-dimethyl-
pyridinium)-pentyl]-benzene dibromide 
Br 
Br 
-
("( NY 
2B,El 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (270 mg, 
0.72 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 355 mg of the title 
compound. Yield: 84%. 1 H NMR (300 MHz, CD30D) o 
1.52 (m, 4H), 1.68 (m, 4H), 2.01 (m, 4H), 2.61 (s, 6H), 2.68 
42 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (270 mg, 
0.72 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
5 solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 329 mg of the title 
compound. Yield: 78 1H NMR (300 MHz, CD30D) o 1.43 
(m, 4H), 1.65 (m, 4H), 2.03 (m, 4H), 2.48 (s, 6H), 2.59 (s, 
6H), 2.64 (t, 1=7.5 Hz, 4H), 4.54 (t, 1=7.5 Hz, 4H), 7.02-7.17 
10 (m, 4H), 7.85 (d, 1=6.3 Hz, 2H), 8.67 (d, 1=4.8 Hz, 2H), 8.77 
(s, 2H) ppm; 13C NMR (75 MHz, CD30D) o 17.3, 20.6, 
27.1, 31.9, 32.4, 33.3, 61.8, 126.9, 129.4, 130.2, 139.7, 
140.9, 142.4, 144.0, 159.5 ppm. 
15 
20 
25 
30 
Example 39 
Synthesis of Compound 1,2-bis-[5-(3,5-dimethyl-
pyridinium)-pentyl]-benzene dibromide [GZ 584 A] 
Br 
~ 
-# 
Br 
(t, 1=7.5 Hz, 4H), 2.82 (s, 6H), 4.53 (t, 1=7.8 Hz, 4H), 
35 
7.02-7.19 (m, 4H), 7.73 (dd, 1=6.3, 1.2 Hz, 2H), 7.82 (d, w 1-1.5 Hz, 2H), 8.72 (d, 1=6.3 Hz, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o 20.5, 22.0, 27.4, 31.2, 32.0, 33.4, 58.4, 127.0, 127.6, 130.3, 131.6, 141.0, 145.4, 155.2, 160.2 ppm. 
Example 38 
Synthesis of Compound 1 ,2-bis-[5-(3,4-dimethyl-
pyridinium)-pentyl]-benzene dibromide [GZ 584 B] 
Br 
-
Br 
40 
45 
50 
55 
N 
N 
M 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (290 mg, 
0.77 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
60 solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 321 mg of the title 
compound. Yield: 71%. 1H NMR (300 MHz, CD3 0D) o 
1.50 (m, 4H), 1.65 (m, 4H), 2.12 (m, 4H), 2.58 (s, 12H), 2.64 
(t, 1=6.3 Hz, 4H), 4.68 (t, 1=7.5 Hz, 4H), 7.02-7.19 (m, 4H), 
65 8.33 (s, 2H), 8.91 (s, 4H) ppm; 13C NMR (75 MHz, CD3 0D) 
0 18.7, 27.2, 31.9, 32.5, 33.4, 62.5, 126.9, 130.2, 140.0, 
140.9, 142.6, 147.7 ppm. 
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Example 40 
Synthesis of Compound 
1,2-bis-[5-quinolinium-pentyl)-benzene dibromide 
Br 
-
Br 
10 
44 
-continued 
~~ 
2Bf3 
00 N 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (271 mg, 
0.72 mmol) and isoquinoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
15 ether and then dissolved in water (20 mL), the aqueous 
solution was extracted with chloroform (20 mLx3). Water 
was removed by lyophilization to afford 392 mg of the title 
compound. Yield: 86%. 1H NMR (300 MHz, CD3 0D) o 
1.38-1.70 (m, 8H), 2.20 (m, 4H), 2.52 (t, 1=7.2 Hz, 4H), 4.92 
20 (t, 1=7.5 Hz, 4H), 6.83-7.05 (m, 4H), 7.99 (dd, 1=6.9, 1.2 Hz, 
2H), 8.18 (dt, 1=8.1, 0.9, 2H), 8.28 (d, 1-8.4 Hz, 2H), 
8.45-8.60 (m, 4H), 8.84 (dd, 1=6.9, 1.2 Hz, 2H), 10.21 (s, 
2H) ppm; 13C NMR (75 MHz, CD3 0D) o 27.0, 31.6, 32.2, 
25 33.1, 62.5, 126.7, 127.2, 128.2, 128.5, 129.9, 131.2, 132.2, 
135.6, 137.9, 138.3, 140.6, 150.3 ppm. 
30 
Example 42 
Synthesis of Compound 
1 ,2-bis-[ 5-(2' -S-nicotinium -pentyl) ]benzene 
dibromide 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (282 mg, 
0.75 mmol) and quinoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 35 
ether and then dissolved in water (20 mL), the aqueous 
solution was extracted with chloroform (20 mL *3 ). Water 
was removed by lyophilization to afford 411 mg of the title 
Br 
compound. Yield: 86%. 1H NMR (300 MHz, CD30D) o I 
1.41-1.73 (m, 8H), 2.13 (m, 4H), 2.47 (t, 1=6.6 Hz, 4H), 5.22 40 
(t, 1=7.5 Hz, 4H), 6.91 (m, 4H), 8.00 (t, 1=7.8 Hz, 2H), 8.16 
~ 
-~ 
(m, 2H), 8.31 (t, 1-7.2 Hz, 2H), 8.44 (d, 1-7.8 Hz, 2H), 8.65 Br 
(d, 1=8.7 Hz, 2H), 9.30 (d, 1=8.1 Hz, 2H), 9.70 (d, 1=5.4 Hz, 
2H) ppm; 13C NMR (75 MHz, CD3 0D) o27.3, 30.9, 31.6, 
33.1, 59.2, 119.8, 123.0, 126.7, 129.8, 131.0, 131.1, 131.8, 45 
137.1, 138.6, 140.6, 148.6, 150.2 ppm. 0'"".0 10 \ 
Example 41 
Synthesis of Compound 
1,2-bis-[5-isoquinolinium-pentyl)-benzene 
dibromide [GZ 585 B] 
Br 
-
Br 
50 
55 
~ CH3 
2Bf3 
Olo' I N 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (278 mg, 
0.74 mmol) and S-nicotine (1 mL) was heated at 60-70° C. 
60 for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (20 mL), the aqueous 
solution was extracted with chloroform (20 mLx3), Water 
was removed by lyophilization to afford 390 mg of the title 
compound. Yield: 75%. 1H NMR (300 MHz, CD3 0D) o 
65 1.40-1.75 (m, 8H), 2.08-2.45 (m, 10H), 2.67 (s, 6H), 2.55-
2.75 (m, 8H), 3.07 (m, 2H), 3.67 (m, 2H), 4.43 (t, 1=6.9 Hz, 
4H), 7.02-7.22 (m, 4H), 8.24 (dd, 1=7.8, 6.3 Hz, 2H), 8.85 
US 9,499,518 B2 
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(d, 1=8.1 Hz, 2H), 9.17 (d, 1=6.0 Hz, 2H), 9.39 (s, 2H) ppm; 
13C NMR (75 MHz, CD3 0D) o23.4, 27.1, 31.8, 32.2, 33.2, 
33.7, 40.2, 57.6, 63.2, 68.9, 126.9, 129.6, 130.2, 139.8, 
140.9, 145.8, 146.4 ppm. 
Example 43 
Synthesis of Compound 
1,2-bis-[5-(3-n-butyl-pyridinium)-pentyl]-benzene 
dibromide 
-
10 
46 
-continued 
~ 
h~ 
Br 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (235 mg, 
0.72 mmol) and 3-bromopyridine (1 mL) was heated at 
15 60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 410 
mg of the title compound. Yield: 95%. 1H NMR (300 MHz, 
20 
CD30D) o 1.30-1.75 (m, 8H), 2.13 (m, 4H), 2.63 (t, 1=7.5 
Hz, 4H), 4.79 (t, 1=7.5 Hz, 4H), 7.00-7.21 (m, 4H), 8.12 (dd, 
1-8.1, 6.0 Hz, 2H), 8.84 (d, 1=7.8 Hz, 2H), 9.24 (d, 1=5.7 Hz, 
2H), 9.58 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o27.2, 
31.9, 32.5, 33.4, 63.2, 124.0, 127.0, 130.2, 140.9, 144.9, 
147.1, 149.4 ppm. 
Example 45 
Synthesis of Compound 
1,2-bis-[5-pyridinium-pentyl)-benzene dibromide 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (232 mg, 
0.62 mmol) and 4-n-butylpyridine (0.5 mL) was heated at 35 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with chloroform (20 mLx3). 
Br 
Water was removed by lyophilization to afford 154 mg of the ~ 
title compound. Yield: 39%. 1H NMR (300 MHz, CD3 0D) 
40 I -
o 0.98 (t, 1=7.2 Hz, 6H), 1.30-1.87 (m, 16H), 2.09 (m, 4H), # 
2.64 (t, 1=7.5 Hz, 4H), 2.92 (t, 1-7.2 Hz, 4H), 4.70 (t, 1=6.6 
Hz, 4H), 6.98-7.18 (m, 4H), 8.05 (dd, 1=8.1, 5.4 Hz, 2H), Br 
8.49 (d, 1=8.1 Hz, 2H), 9.95 (d, 1=5.7 Hz, 2H), 10.08 (s, 2H) 
45 
ppm; 13C NMR (75 MHz, CD30D) o14.4, 23.3, 27.2, 31.9, 
32.6, 33.3, 33.4, 33.8, 62.8, 127.0, 128.9, 130.3, 140.9, 
143.3, 145.2, 145.5, 146.5 ppm. 
Example 44 
Synthesis of Compound 
1,2-bis-[5-(3-bromo-pyridinium)-pentyl]-benzene 
dibromide 
Br 
-
Br 
50 
55 
~ 
hV 
A mixture of 1 ,2-bis-(5-bromo-pentyl)-benzene (244 mg, 
0.65 mmol) and pyridine (1 mL) was heated at 60-70° C. for 
12 hrs. The resulted mixture was washed with diethyl ether 
and then dissolved in water (15 mL), the aqueous solution 
60 
was extracted with diethyl ether (30 mLx3). Water was 
removed by lyophilization to afford 317 mg of the title 
compound. Yield: 92%. 1H NMR (300 MHz, CD3 0D) o 
1.48 (m, 4H), 1.65 (m, 4H), 2.10 (m, 4H), 2.63 (t, 1-7.5 Hz, 
4H), 4.74 (t, 1=7.5 Hz, 4H), 7.02-7.20 (m, 4H), 8.16 (t, 1=6.9 
65 Hz, 4H), 8.64 (t, 1=7.8 Hz, 2H), 9.13 (d, 1=5.4 Hz, 4H) ppm; 
13C NMR (75 MHz, CD3 0D) o27.1, 31.9, 32.5, 33.3, 62.9, 
127.0, 129.4, 130.3, 140.9, 145.8, 146.7 ppm. 
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Example 46 
Synthesis of Compound 5-[3-(5-hydroxy-pent-1-
ynyl)-phenyl]-pent-4-yn-1-ol 
Br 
QR, -
OH 
II 
OH 
1,3-Dibromobenzene (7.48 g, 31.71 mmol), 4-pentyn-1-ol 
(6.40 g, 76.10 mmol), and &M(triphenylphosphine)palladi-
um(II) dichloride ( 445 mg, 0.63 mmol) was stirred in 
triethylamine (150 mL) under nitrogen for 5 min. Copper(!) 
iodide (61 mg, 0.32 mmol) was added and the mixture was 
stirred for 18 hrs at 75° C. The mixture was cooled to room 
10 
15 
48 
-continued 
Br 
II 
Br 
5-[3-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol 
(2.86 g, 11.80 mmol) and carbon tetrabromide (9.78 g, 29.50 
mmol) were dissolved in dry methylene chloride (30 mL) 
20 
and cooled to oo C. Triphenyl phosphine (8.13 g, 30.98 
mmol) in methylene chloride (20 mL) was added dropwise 
and the mixture was stirred for 1 h at oo C. The mixture was 
poured into hexanes (200 mL) and then filtered through a 
short silica gel column, washed with ethylacetate/hexanes 
25 
(1/4). The combined organic solvents were evaporated to 
dryness under reduced pressure. The resulting residue was 
purified by colunm chromatography (hexanes:ethylacetate 
30:1) to afford 3.64 g of the title compound. Yield: 84%. 1H 
NMR (300 MHz, CDC13 ) o 2.13 (m, 4H), 2.60 (t, 1=6.6 Hz, 
30 
4H), 3.58 (dt, 1=6.6 Hz, 4H), 7.18-7.32 (m, 3H), 7.43 (t, 
1=1.5 Hz, lH) ppm; 13C NMR (75 MHz, CDC13 ) o 18.4, 
31.7, 32.7, 81.1, 88.7, 123.8, 128.4, 131.0, 134.8 ppm. 
Example 48 
35 
temperature and filtered through a celite pad, rinsed with Synthesis of Compound 1,3-bis-[5-(2-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide ethylacetate. The combined filtrate was evaporated to dry-
ness under reduced pressure. The resulting residue was 
purified by colunm chromatography ( chloroform:methanol 
20:1) to afford 7.24 g of the title compound. Yield: 94%. 1H 
40 
NMR (300 MHz, CDC13 ) o 1.85 (m, 4H), 2.53 (t, 1=6.9 Hz, 
4H), 3.81 (t, 1=6.0 Hz, 4H), 7.16-7.31 (m, 3H), 7.42 (t, 1=1.2 
Hz, lH) ppm; 13C NMR (75 MHz, CDC13 ) o 16.2, 31.6, 
61.9, 80.6, 90.0, 124.0, 128.3, 130.8, 134.7 ppm. 
Example 47 
Synthesis of Compound 
1 ,3-bis-(5-bromo-pent-1-ynyl)-benzene 
OH 
II -
OH 
45 
50 
55 
60 
65 
Br 
II 
Br 
-
(') NY 
e 
2 Br 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(368 mg, 1.00 mmol) and 2-picoline (1.5 mL) was heated at 
US 9,499,518 B2 
49 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 472 
mg of the title compound. Yield: 84%. 1 H NMR (300 MHz, 5 
CD3 0D) o2.29 (m, 4H), 2.69 (t, 1=6.6 Hz, 4H), 2.97 (s, 6H), 
4.81 (t, 1=7.5 Hz, 4H), 7.23-7.38 (m, 3H), 7.43 (d, 1=1.5 Hz, 
IH), 7.95 (t, 1=6.9 Hz, 2H), 8.01 (d, 1=7.8 Hz, 2H), 8.43 (dt, 
1=7.8, 1.5 Hz, 2H), 8.99 (dd, 1=6.3, 1.5 Hz, 2H) ppm; 13C 
NMR (75 MHz, CD3 0D) o17.4, 20.9, 29.9, 58.3, 82.1, 89.6, 
10 
124.7, 127.0, 129.8, 131.5, 132.2, 135.2, 146.5, 146.6, 156.8 
ppm. 
50 
Example 50 
Synthesis of Compound 1 ,3-bis-[5-( 4-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
Br 
II 
--
Example 49 15 I 
Synthesis of Compound 1,3-bis-[5-(3-methyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
Br 
II 
--
~ Br 
Q N 
e 
20 
25 
30 
35 
40 
0 
45 
I N 
2 Br 
50 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(348 mg, 0.94 mmol) and 3-picoline (1.5 mL) was heated at 55 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 469 
60 
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz, 
CD3 0D) o2.35 (m, 4H), 2.56 (s, 6H) 2.63 (t, 1=6.6 Hz, 4H), 
4.80 (t, 1=7.2 Hz, 4H), 7.22-7.33 (m, 3H), 7.37 (s, IH), 8.00 
(dd, 1=8.1, 6.3 Hz, 2H), 8.39 (d, 1=7.8 Hz, 2H), 8.91 (d, 1-6.3 
Hz, 2H), 9.00 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o 65 
17.3, 18.8, 31.0, 62.1, 82.1, 89.4, 124.7, 128.7, 129.7, 132.1, 
135.4, 141.1, 143.3, 145.7, 147.4 ppm. 
Br 
~ 
hV 
e 
2 Br 
~ 
hV 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(350 mg, 0.94 mmol) and 4-picoline (1.5 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 478 
mg of the title compound. Yield: 92%. 1 H NMR (300 MHz, 
CD30D) o2.33 (m, 4H), 2.58 (s, 6H), 2.63 (t, 1=6.6 Hz, 4H), 
4.77 (t, 1=6.9 Hz, 4H), 7.28 (s, 4H), 7.93 (d, 1=6.3 Hz, 4H), 
8.90 (d, 1=6.6 Hz, 4H) ppm; 13C NMR (75 MHz, CD3 0D) 
0 17.3, 22.3, 30.8, 61.4, 81.9, 89.5, 124.7, 129.9, 132.1, 
135.2, 145.0, 161.2 ppm. 
II 
Example 51 
Synthesis of Compound 1,3-bis-[5-(2,4-dimethyl-
pyridinium)-pent-1-ynyl]-benzene dibromide 
Br 
--
Br 
US 9,499,518 B2 
II 
51 
-continued 
r:l( NY 
e 
2 Br 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(249 mg, 0.68 mmol) and 2,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 357 
mg of the title compound. Yield: 91%. 1 H NMR (300 MHz, 
CD3 0D) o2.29 (m, 4H), 2.51 (s, 3H), 2.73 (t, 1=6.6 Hz, 4H), 
2.94 (s, 3H), 4.79 (t, 1=7.5 Hz, 4H), 7.33 (d, 1=0.9 Hz, 4H), 
7.78 (dd, 1=6.6, 2.1 Hz, 2H), 7.85 (s, 2H), 8.89 (d, 1=6.6 Hz, 
2H) ppm; 13C NMR (75 MHz, CD3 0D) o17.4, 20.6, 22.0, 
29.9, 57.6, 82.0, 89.7, 124.8, 127.6, 129.9, 131.7, 132.1, 
135.1, 145.6, 155.5, 160.5 ppm. 
II 
Example 52 
Synthesis of Compound 1 ,3-bis-[5-(3,4-dimethyl-
pyridiniiim)-pent-1-ynyl]-benzene dibromide [GZ 
570 B] 
Br 
II 
-
Br 
eY 
h~ 
e 
2 Br 
~ 
E0 
52 
diethyl ether and then dissolved in water (15 mL), the 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 261 
mg of the title compound. Yield: 65%. 1 H NMR (300 MHz, 
5 CD30D) o 2.36 (s, 3H), 2.43 (s, 3H), 2.47 (m, 4H), 2.66 (t, 
1=6.6 Hz, 4H), 4.77 (t, 1=6.9 Hz, 4H), 7.18-7.36 (m, 4H), 
7.87 (d, 1=6.3 Hz, 2H), 8.82 (d, 1=6.3 Hz, 2H), 8.92 (s, 2H), 
ppm; 13C NMR (75 MHz, CD30D) o17.2, 17.4, 20.4, 30.8, 
61.5, 81.9, 89.5, 124.9, 129.5, 129.8, 132.0, 135.3, 139.8, 
10 142.9, 144.5, 160.0 ppm. 
15 
20 
25 
30 
35 
40 
45 
50 
55 
Example 53 
Synthesis of Compound 1,3-bis-[5-(3,5-dimethyl-
pyridinium)-pent-1-ynyl]-benzene dibromide 
Br 
II 
-~ 
# 
Br 
Q 
N 
II 
e 
2 Br 
Q ~ N 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(249 mg, 0.68 mmol) and 3,5-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 
60 
aqueous solution was extracted with diethyl ether (30 
mL *3). Water was removed by lyophilization to afford 356 
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz, 
CD30D) o2.35 (m, 4H), 2.51 (s, 6H), 2.64 (t, 1=6.3 Hz, 4H), 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 65 
(253 mg, 0.69 mmol) and 3,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
4.75 (t, 1=7.2 Hz, 4H), 7.28 (d, 1=1.2 Hz, 3H), 7.33 (s, lH), 
8.19 (s, 2H), 8.82 (s, 4H) ppm; 13C NMR (75 MHz, CD3 0D) 
0 17.4, 18.7, 31.0, 61.8, 81.9, 89.7, 124.6, 129.7, 132.0, 
135.2, 140.1, 142.8, 147.9 ppm. 
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Example 54 
Synthesis of Compound 
1 ,3-bis-( 5-quinolinium-pent-1-ynyl)-benzene 
dibromide [GZ571A] 
Br 
--
Br 
10 
15 
54 
-continued 
~ 
hVV 
e I N 
0 
2 Br 
A mixture of 1,3-&fs-(5-bromo-pent-1-ynyl)-benzene 
(257 mg, 0.70 mmol) and isoquinoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
20 ~~~~~~s :t~l~ti~~~!~:~t~;~:~lv~fthi~h~~~%~~2~~Lxt~)~ 
Water was removed by lyophilization to afford 316 mg of the 
title compound. Yield: 72%. 1H NMR (300 MHz, CD3 0D) 
o 2.47 (m, 4H), 2.74 (t, 1=6.3 Hz, 4H), 5.01 (t, 1=6.9 Hz, 
4H), 6.54 (s, lH), 6.85-7.03 (m, 3H), 8.01 (dt, 1=6.0, 1.5 Hz, 
25 2H), 8.11-8.22 (m, 4H), 8.40-8.57 (m, 4H), 8.79 (dd, 1=6.9, 
1.2 Hz, 2H), 10.15 (s, 2H) ppm; 13C NMR (75 MHz, 
CD30D) o17.6, 30.6, 62.6, 82.0, 89.2, 124.4, 127.5, 128.4, 
129.2, 129.3, 131.5, 131.7, 132.5, 134.7, 136.0, 138.4, 
139.1, 151.5 ppm. 
30 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(253 mg, 0.69 mmol) and quinoline (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (30 mL), the 35 
aqueous solution was extracted with chloroform (20 mLx3). 
Water was removed by lyophilization to afford 271 mg of the 
title compound. Yield: 63%. 1H NMR (300 MHz, CD3 0D) 
o 2.45 (m, 4H), 2.73 (t, 1=6.6 Hz, 4H), 5.31 (t, 1=7.5 Hz, 
4H), 7.14 (d, 1-1.2 Hz, lH), 7.20-7.30 (m, 3H), 8.02-8.17 40 
(m, 4H), 8.31 (dt, 1=7.2, 1.2 Hz, 2H), 8.41 (dd, 1=8.4, 1.5 
Hz, 2H), 8.67 (d, 1=9.0 Hz, 2H), 9.17 (d, 1=8.7 Hz, 2H), 9.54 
(dd, 1=5.7, 1.5 Hz, 2H) ppm; 13C NMR (75 MHz, CD3 0D) 
Example 56 
Synthesis of Compound 1,3-bis-[5-(2'-S-nicotinium-
pent -1-yny I) ]benzene dibromide 
Br 
II 
--0 17.5, 29.6, 58.7, 81.8, 89.8, 119.7, 123.1, 124.4, 129.6, 
131.2, 131.4, 131.9, 132.1, 135.0, 137.3, 139.1, 149.1, 150.6 45 I 
ppm. 
II 
Example 55 
Synthesis of Compound 
1 ,3-bis-( 5-isoquinolinium-pent-1-ynyl)-benzene 
dibromide 
Br 
--
Br 
50 
55 
60 
65 
0 
~ 2Br 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(244 mg, 0.66 mmol) and S-nicotine (1 mL) was heated at 
US 9,499,518 B2 
55 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (20 mL), the 
aqueous solution was extracted with chloroform (20 mLx3). 
Water was removed by lyophilization to afford 388 mg of the 
title compound. Yield: 85%. 1H NMR (300 MHz, CD3 0D) 5 
o 1.75-2.15 (m, 6H), 2.35 (s, 6H), 2.33-2.50 (m, 6H), 2.63 
(t, 1=6.6 Hz, 4H), 3.37 (m, 2H), 3.74 (m, 2H), 4.87 (t, 1=6.9 
Hz, 4H), 7.23-7.35 (m, 3H), 7.41 (s, lH), 8.12 (dd, 1-8.1, 6.0 
Hz, 2H), 8.61 (dd, 1=7.8, 0.9 Hz, 2H), 9.03 (dd, 1=6.0, 0.9 
Hz, 2H), 9.18 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o 
10 
17.2, 23.9, 30.8, 35.5, 40.7, 57.8, 62.3, 68.5, 82.2, 89.3, 
124.7, 129.4, 129.7, 132.2, 135.4, 144.9, 145.1, 145.4, 146.1 
ppm. 
15 
Example 57 
Synthesis of Compound 1,3-bis-[5-(3-n-butyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 20 
Br 
25 
II 
- 30 
Br 
35 
~ N 40 
II 
0 45 
~ 2 Br 
# 
~ ~ N 50 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(242 mg, 0.66 mmol) and 4-n-butylpyridine (0.5 mL) was 
heated at 60-70° C. for 12 hrs. The resulted mixture was 55 
washed with diethyl ether and then dissolved in water (30 
mL), the aqueous solution was extracted with chloroform 
(20 mLx3). Water was removed by lyophilization to afford 
347 mg of the title compound. Yield: 83%. 1H NMR (300 
MHz, CD30D) o 0.98 (t, 1=7.2 Hz, 6H), 0.95 (t, 1=7.2 Hz, 60 
6H), 1.40 (m, 4H), 1.67 (m, 4H), 2.39 (m, 4H), 2.67 (t, 1=6.6 
Hz, 4H), 2.88 (t, 1=7.8 Hz, 4H), 4.90 (t, 1=6.9 Hz, 4H), 7.29 
(d, 1=1.2 Hz, 3H), 7.33 (s, lH), 8.07 (dd, 1=7.8, 6.0 Hz, 2H), 
8.45 (d, 1=8.1 Hz, 2H), 9.04 (d, 1-6.3 Hz, 2H), 9.14 (s, 2H) 
ppm; 13C NMR (75 MHz, CD30D) o14.4, 17.3, 23.3, 31.0, 65 
33.3, 33.6, 62.1, 82.1, 89.4, 124.7, 129.0, 129.7, 132.2, 
135.4, 143.5, 145.4, 145.5, 146.8 ppm. 
56 
Example 58 
Synthesis of Compound 1,3-bis-[5-(3-phenyl-pyri-
dinium)-pent-1-ynyl]-benzene dibromide 
Br 
II 
-
0 
2 Br 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(243 mg, 0.66 mmol) and 3-bromopyridine (0.5 mL) was 
heated at 60-70° C. for 12 hrs. The resulted mixture was 
washed with diethyl ether and then dissolved in water (30 
mL), the aqueous solution was extracted with chloroform 
(20 mLx3). Water was removed by lyophilization to afford 
390 mg of the title compound. Yield: 87%. 1 H NMR (300 
MHz, CD3 0D) o 2.41 (m, 4H), 2.70 (t, 1=6.6 Hz, 4H), 5.00 
(t, 1=6.9 Hz, 4H), 7.15 (d, "1=1.2 Hz, lH), 7.18 (m, 3H), 
7.45-7.58 (m, 6H), 7.77-7.87 (m, 4H), 8.14 (dd, 1-8.1, 6.0 
Hz, 2H), 8.74 (ddd, 1=8.1, 1.5, 1.2 Hz, 2H), 9.13 (d, 1=6.0 
Hz, 2H), 9.56 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o 
17.4, 30.9, 62.4, 82.0, 89.5, 124.5, 128.6, 129.5, 129.6, 
130.6, 131.4, 132.0, 134.1, 135.3, 142.1, 143.9, 144.0, 144.2 
ppm. 
II 
Example 59 
Synthesis of Compound 
1 ,3-bis-( 5-pyridinium-pent-1-ynyl)-benzene 
dibromide 
Br 
-
Br 
US 9,499,518 B2 
57 
-continued 
0 N 
II 
El 
~ 2Br 
0 N 
58 
psi) for 12 hrs. The catalyst was removed by filtration 
through a Celite pad. The filter cake was rinsed with 
methanol, and the combined organic liquors were concen-
trated under reduced pressure. The crude product was puri-
5 fied by colunm chromatography ( chloroform:methanol 20:1) 
to afford 3.12 g of the title compound. Yield: 89%. 1H NMR 
(300 MHz, CDC13 ) o 1.30-1.45 (m, 4H), 1.50-1.72 (m, 8H), 
2.59 (t, 1=7.8 Hz, 4H), 3.62 (t, 1=6.6 Hz, 4H), 6.99 (m, 3H), 
7.18 (m, lH) ppm; 13C NMR (75 MHz, CDC13 ) o25.7, 31.5, 
10 32.8, 36.1, 63.0, 125.8, 128.3, 128.7, 142.5 ppm. 
Example 61 
15 
Synthesis of Compound 
A mixture of 1,3-bis-(5-bromo-pent-1-ynyl)-benzene 
(240 mg, 0.65 mmol) and pyridine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL), the 20 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 322 
mg of the title compound. Yield: 94%. 1H NMR (300 MHz, 
CD3 0D) o 2.40 (m, 4H), 2.68 (t, 1=6.9 Hz, 4H), 4.94 (t, 
1=7.5 Hz, 4H), 7.32 (m, 3H), 7.39 (d, 1=1.2 Hz, lH), 8.19 25 
(dd, 1=7.8, 6.9 Hz, 4H), 8.63 (m, 2H), 9.23 (dd, 1=7.2, 1.2 
Hz, 4H) ppm; 13C NMR (75 MHz, CD30D) o 17.2, 31.0, 
62.1, 82.1, 89.4, 124.6, 129.4, 129.7, 132.2, 135.3, 146.0, 
1 ,3-bis-( 5-bromo-pentyl)-benzene 
OH 
--
146.9 ppm. 
Example 60 
Synthesis of Compound 
5-[3-( 5-hydroxy-pentyl)-phenyl]-pentan-1-ol 
OH 
--
OH 
OH 
OH 
5-[3-( 5-Hydroxy-pent-1-ynyl)-phenyl]-pent-4-yn-1-ol 
(3.40 g, 14.03 mmol) was dissolved in methanol (60 mL) 
and 10% Pd!C (2.5% w/w) was added. The resulting mixture 
was hydrogenated on a Parr hydrogenation apparatus ( 45 
OH 
35 
40 
Br 
45 
50 5-[3-(5-Hydroxy-pentyl)-phenyl]-pentan-1-ol (2.26 g, 
9.03 mmol) and carbon tetrabromide (7.49 g, 22.58 mmol) 
were dissolved in dry methylene chloride (20 mL) and 
cooled to oo C. Triphenylphosphine (6.22 g, 23.70 mmol) 
55 in methylene chloride (15 mL) was added dropwise and the 
mixture was stirred for 1 h at oo C. The mixture was poured 
into hexanes (200 mL) and then filtered through a short silica 
gel column, washed with ethylacetate/hexanes (1/4). The 
combined organic solvents were evaporated to dryness 
60 under reduced pressure. The resulting residue was purified 
by colunm chromatography (hexanes:ethylacetate30: 1) to 
afford 2.80 g of the title compound. Yield: 82%. 1 H NMR 
(300 MHz, CDC13 ) o1.46 (m, 4H), 1.61 (m, 4H), 1.88 (m, 
65 4H), 2.59 (t, 1=7.8 Hz, 4H), 3.40 (t, 1=6.9 Hz, 4H), 7.00 (m, 
3H), 7.19 (m, lH) ppm; 13C NMR (75 MHz, CDC13 ) o28.1, 
30.9, 32.9, 34.1, 36.0, 125.9, 128.3, 128.6, 142.4 ppm. 
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Example 62 
Synthesis of Compound 
1,3-bis-[5-(2-methyl-pyridinium)-pentyl]-benzene 
dibromide 
--
Br 
10 
15 
60 
-continued 
~ 
~~ 
e 
2Br 
A 
E0 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (265 mg, 
0.70 mmol) and 3-picoline (1 ml) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
(e') NY 
20 ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 362 mg of the title 
compound. Yield: 91%. 1H NMR (300 MHz, CD3 0D) o 
1.44 (m, 4H), 1.69 (m, 4H), 2.10 (m, 4H), 2.59 (t, 1=7.8 Hz, 
e 
2Br 
25 4H), 2.62 (s, 6H), 4.70 (t, 1=7.5 Hz, 4H), 6.94-7.09 (m, 3H), 
7.16 (t, 1=1.5 Hz, lH), 8.03 (dd, 1=8.1, 6.0 Hz, 2H), 8.48 (d, 
1=8.1 Hz, 2H), 8.96 (d, 1=6.0 Hz, 2H), 9.08 (s, 2H) ppm; 13C 
NMR (75 MHz, CD3 0D) o18.9, 26.6, 31.9, 32.3, 36.5, 62.6, 
126.9, 128.6, 129.3, 129.6, 140.9, 142.9, 143.3, 145.3, 147.1 
30 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (240 mg, 
0.64 mmol) and 2-picoline (1 mL) was heated at 60-70° C. 35 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 328 mg of the title 
compound. Yield: 91%. 1H NMR (300 MHz, CD30D) o 40 
1.54 (m, 4H), 1.73 (m, 4H), 2.02 (m, 4H), 2.63 (t, 1=7.5 Hz, 
4H), 2.95 (s, 6H), 4.67 (t, 1-7.5 Hz, 4H), 6.98-7.22 (m, 4H), 
7.97 (t, 1=6.9 Hz, 2H), 8.07 (d, 1=8.1 Hz, 2H), 8.49 (t, 1=7.8 
Hz, 2H), 9.05 (d, 1=6.3 Hz, 2H) ppm; 13C NMR (75 MHz, 
CD3 0D) o20.9, 26.9, 31:0, 32.0, 36.5, 59.2, 126.85, 126.88, 45 
129.3, 129.6, 131.4, 143.3, 146.2, 146.3, 156.4 ppm. 
Example 63 
Synthesis of Compound 
1,3-bis-[5-(3-methyl-pyridinium)-pentyl]-benzene 
dibromide 
--
Br 
50 
55 
60 
65 
ppm. 
Example 64 
Synthesis of Compound 
1 ,3-bis-[ 5-( 4-methyl-pyridinium)-pentyl]-benzene 
dibromide 
--
Br 
~ 
~v 
e 
2Br 
~ 
~v 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (240 mg, 
0.64 mmol) and 4-picoline (1 mL) was heated at 60-70° C. 
US 9,499,518 B2 
61 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 332 mg of the title 
compound. Yield: 92%. 1 H NMR (300 MHz, CD30D) o 5 
1.42 (m, 4H), 1.67 (m, 4H), 2.06 (m, 4H), 2.59 (t, 1-7.5 Hz, 
4H), 2.69 (s, 6H), 4.66 (t, 1=7.5 Hz, 4H), 6.95-7.08 (m, 3H), 
7.16 (t, 1=7.5 Hz, lH), 7.97 (d, 1=6.3 Hz, 4H), 8.94 {d, 1=6.3 
Hz, 4H) ppm; 13C NMR (75 MHz, CD30D) o 22.4, 26.6, 
31.9, 32.2, 36.5, 61.9, 126.9, 129.3, 129.6, 129.8, 143.3, 10 
144.7, 160.7 ppm. 
Example 65 
Synthesis of Compound 1 ,3-bis-[5-(2,4-dimethyl-
pyridinium)-pentyl]-benzene dibromide 
-
Br 
y N 
e 
2Br 
15 
20 
25 
30 
35 
40 
~45 
/..hV 
50 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (237 mg, 
0.63 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C. 
55 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 323 mg of the title 
compound. Yield: 87%. 1 H NMR (300 MHz, CD30D) o 60 
1.51 (m, 4H), 1.71 (m, 4H), 1.99 (m, 4H), 2.62 (t, 1=7.5 Hz, 
4H), 2.64 (s, 6H), 2.87 (s, 6H), 4.58 (t, 1=7.5 Hz, 4H), 
6.96-7.12 (m, 3H), 7.17 (t, 1-7.5 Hz, lH), 7.78 (dd, 1=6.6, 
1.5 Hz, 2H), 7.89 (d, 1=1.5 Hz, 2H), 8.82 (d, 1=6.6 Hz, 2H) 
ppm; 13C NMR (75 MHz, CD30D) o20.5, 22.1, 26.9, 31.1, 
32.1, 36.6, 58.4, 126.9, 127.5, 129.3, 129.6, 131.6, 143.3, 
145.3, 155.1, 160.1 ppm. 
62 
Example 66 
Synthesis of Compound 1,3-bis-[5-(3,4-dimethyl-
pyridinium)-pentyl]-benzene dibromide [GZ 578 B] 
-
Br 
~ 
~~ 
e 
2Br 
~ 
E0 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (235 mg, 
0.62 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 350 mg of the title 
compound. Yield: 97%. 1H NMR (300 MHz, CD3 0D) o 
1.44 (m, 4H), 1.68 (m, 4H), 2.09 (m, 4H), 2.51 (s, 6H), 2.59 
(t, 1=7.8 Hz, 4H), 2.60 (s, 6H), 4.65 (t, 1-7.5 Hz, 4H), 
6.96-7.20 (m, 4H), 7.92 ( d, 1=6.3 Hz, 2H), 8.82 ( d, 1=6.3 Hz, 
2H), 8.96 (s, 2H) ppm; 13C NMR (75 MHz, CD3 0D) o17 .3, 
20.7, 26.6, 31.9, 32.2, 36.5, 61.7, 126.8, 129.2, 129.3, 129.5, 
139.6, 142.3, 143.2, 143.9, 159.4 ppm. 
Example 67 
Synthesis of Compound 1,3-bis-[5-(3,5-dimethyl-
pyridinium)-pentyl]-benzene dibromide 
Br 
-
Br 
US 9,499,518 B2 
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-continued 
A 
r~ 
e 
2Br 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (246 mg, 
0.65 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C. 
64 
solution was extracted with chloroform (20 mLx3). Water 
was removed by lyophilization to afford 383 mg of the title 
compound. Yield: 90%. 1H NMR (300 MHz, CD3 0D) o 
1.52 (m, 4H), 1.64 (m, 4H), 2.13 (m, 4H), 2.51 (t, 1=7.5 Hz, 
5 4H), 5.17 (t, 1=7.5 Hz, 4H), 6.81-7.06 (m, 4H), 8.03 (t, 1=7.8 
Hz, 2H), 8.12 (dd, 1=8.4, 6.0 Hz, 2H), 8.31 (dt, 1-6.0, 1.5 Hz, 
2H), 8.45 (dd, 1=8.4, 0.9 Hz, 2H), 8.61 (d, 1=9.0 Hz, 2H), 
9.27 (d, 1=8.4 Hz, 2H), 9.59 (d, 1=5.7 Hz, 2H) ppm; 13C 
NMR (75 MHz, CD30D) o 27.0, 30.9, 31.9, 36.4, 59.3, 
10 119.8, 123.0, 126.8, 129.1, 129.4, 131.2, 131.3, 132.0, 
137.2, 138.9, 143.1, 148.7, 150.2 ppm. 
Example 69 
Synthesis of Compound 
1 ,3-bis-( 5-isoquinolinium-penty I)-benzene 
dibromide [GZ 579 B] 
for 12 hrs. The resulted mixture was washed with diethyl 20 
ether and then dissolved in water (15 mL), the aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 371 mg of the title 
compound. Yield: 96%. 1H NMR (300 MHz, CD30D) o 
1.46 (m, 4H), 1.68 (m, 4H), 2.11 (m, 4H), 2.58 (s, 12H), 2.63 
25 
(t, 1=6.6 Hz, 4H), 4.66 (t, 1=7.5 Hz, 4H), 6.95-7.20 (m, 4H), 
8.34 (s, 2H), 8.92 (s, 4H) ppm; 13C NMR (75 MHz, CD3 0D) -0 18.7, 26.7, 32.0, 32.4, 36.5, 62.3, 126.8, 129.2, 129.5, 
140.0, 142.6, 143.3, 147.6 ppm. 
Example 68 
Synthesis of Compound 
1 ,3-bis-(5-quinolinium-pentyl)-benzene dibromide 
Br 
-
Br 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (253 mg, 
0.67 mmol) and quinoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (30 mL), the aqueous 
30 
35 
40 
45 
50 
Br 
~ 
~~ 
e 
2Br 
e I N 
A mixture of 1 ,3-bis-(5-bromo-pentyl)-benzene (278 mg, 
0.74 mmol) and isoquinoline (1 mL) was heated at 60-70° C. 
55 for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (30 mL), the aqueous 
solution was extracted with chloroform (20 mLx3). Water 
was removed by lyophilization to afford 391 mg of the title 
compound. Yield: 83%. 1H NMR (300 MHz, CD3 0D) o 
60 1.43 (m, 4H), 1.64 (m, 4H), 2.17 (m, 4H), 2.49 (t, 1=7.5 Hz, 
4H), 4.88 (t, 1=7.5 Hz, 4H), 6.81-7.06 (m, 4H), 8.01 (t, 1=7.8 
Hz, 2H), 8.19 (t, 1-7.5 Hz, 2H), 8.28 (d, 1=8.4 Hz, 2H), 8.53 
(t, 1=6.9 Hz, 4H), 8.79 (dd, 1=6.9, 0.9 Hz, 2H), 10.16 (s, 2H) 
65 ppm; 
13C NMR (75 MHz, CD30D) o 26.6, 31.8, 32.2, 36.3, 
62.6, 126.7, 127.4, 128.3, 128.7, 129.1, 129.4, 131.4, 132.3, 
135.7, 138.1, 138.5, 143.1, 150.4 ppm. 
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65 
Example 70 
Synthesis of compound N,N'-[(1,1'-biphenyl)-4,4'-
di -(3-prop any I)]-bis-[3-(2' -S-1-methy 1-pyrrolidin-2-
yl)-pyridinium] dibromide 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu- 20 
tion of 5-nicotine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no S-nicotine left in the aqueous layer. The 25 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 9.10 (s, 2H), 9.01 (d, 1=6.0, 2H), 8.52 (d, 1=7.8, 2H), 
8.05 (dd, 2H), 7.49 (d, 1=8.1, 4H), 7.33 (d, 1=8.1, 4H), 4.79 
(t, 1=7.5, 4H), 3.53 (t, 1=8.1, 2H), 3.23 (m, 2H), 2.83 (t, 30 
1=7.5, 4H), 2.30-2.45 (m, 6H), 2.20 (s, 6H), 1.85-1.97 (in, 
4H). CNMR, 145.85, 144.42, 143.74, 143.54, 139.48, 
138.65, 129.07, 128.23, 126.81, 67.32, 61.64, 56.83, 39.90, 
35.21, 32.87, 31.99, 23.09. 
35 
Example 71 
Br 
66 
Example 72 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di -(3-propanyl) ]-bis-(3,4-dimethy lpyridinium) 
dibromide [ZZ 55 C] 
Br _ 
~ 
~N 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 3,4-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(3-propanyl)]-bis-(3,5-dimethylpyridinium) 
dibromide [ZZ 1 55 D] 
40 with ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.82 (s, 2H), 8.73 (d, 1=6.3, 2H), 7.78 (d, 3=63, 2H), 
7.47 (d, 1=8.4, 4H), 7.29 (d, 1=8.4, 4H), 4.64 (t, 1=7.2, 4H), 
45 2.79 (t, 1=7.2, 4H), 2.470 (s, 6H), 2.32-2.42 (m, 10H). 
A 
k~ 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu- 55 
CNMR, 158.42, 143.02, 141.37, 139.56, 138.50, 138.32, 
129.04, 128.32, 126.56, 60.61, 32.56, 31.97, 19.44, 16.12. 
Example 73 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di -(3-propanyl) ]-bis-(2,4-dimethy lpyridinium) 
dibromide 
tion of3,5-lutidine (3 mmol) in acetonitrile and the solution Br Br _ 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
60 
with ether until no 3,5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHZ, D20, 
ppm), 8.79 (s, 4H), 8.15 (s, 2H), 7.46 (d, 1=8.1, 4H), 7.31 (d, 
1=8.1, 4H), 4.66 (t, 1=7.5, 4H), 2.81 (t, 1=7.5, 2.46 (s, 12H), 65 
2.34-2.39 (m, 4H). CNMR, 146.52, 141.58, 139.58, 139.00, 
138.36, 129.05, 126.55, 61.28, 32.58, 32.05, 17.58. 
~ IN 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 2,4-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
US 9,499,518 B2 
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-continued 
2Br 8 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHZ, D20, 5 
ppm), 8.83 (d, 1=6.3, 2H), 7.79 (d, 1=1.5, 2H), 7.68 (dd, 
1=7.8, 1=1.5, 2H), 7.52 (d, 1=8.4, 4H), 7.37 (d, 1=8.4, 4H), 
4.58 (t, 1=7.5, 4H), 3.60 (t, 1=7.2, 4H), 2.85 (t, 1=7.2, 4H), 
2.75 (s, 6H), 2.54 (s, 6H), 2.22-2.27 (m, 4H). CNMR, 
159.10, 154.11, 144.30, 139.67, 138.39, 130.59, 129.22, 
126.70, 126.55, 56.89, 31.94, 31.73, 31.02, 19.51. 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 5,6,7,8-tetrahydroquinoline (3 mmol) in acetonitrile 
10 and the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no 5,6,7,8-tetrahydroquinoline 
left in the aqueous layer. The resulting aqueous solution of 
Br 
Example 74 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di -(3-propanyl) ]-bis-[3-(3 -hydroxy-propy 1)-pyri-
dinium]dibromide [ZZ 55 G] 
Br _ 
15 the product was lyophilized to yield the pure product. (75% ). 
1H NMR (300 MHz, D20, ppm), 8.79 (d, 1-6.3, 2H), 8.19 (d, 
1=7.2, 2H), 7.77 (dd, 1=6.3, 1=7.8, 2H), 7.54 (d, 1=7.8, 4H), 
7.36 (d, 1=7.8, 4H), 4.59 (t, 1=7.8, 4H), 3.07 (t, 1=6.3, 4H), 
2.97 (t, 1=6.0, 4H), 2.87 (t, 1=7.5, 4H), 2.30 (p, 1=7.5, 4H), 
~ ~ N 
20 
1.93-1.99 (m, 4H), 1.81-1.87 (m, 4H). CNMR, 154.12, 
145.55, 143.40, 139.94, 139.38, 138.83, 128.99, 126.66, 
124.51, 56.85, 31.93, 31.52, 28.77, 26.88, 21.54, 20.63. ~ 
( 25 Example 76 
OH OH 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 3-(3-hydroxypropyl)-pyridine (3 mmol) in acetoni-
Br 
~ 
~~ 
trile and the solution refluxed for 24 hours. The acetonitrile 
was removed in vacuum and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no 3-(3-Hydroxypro-
pyl)-pyridine left in the aqueous layer. The resulting aqueous 
solution of the product was lyophilized to yield the pure 
product. (75%). 1H NMR (300 MHz, D20, ppm), 8.96 (s, 
2H), 8.87 (d, 1=6.0, 2H), 8.42 (d, 1=7.8, 2H), 7.96 (dd, 1=6.0, 
1=7.8, 2H), 7.48 (d, 1=8.1, 4H) 5 7.29 (d, 1=8.1, 4H), 4.70 
(t, 1=7.5, 4H), 3.60 (t, 1=6.3, 4H), 2.92 (t, 1=6.3, 4H), 2.81 
(t, 1=7.5, 4H), 2.41 (p, 3=72, 4H), 1.87-1.95 (m, 4H). 
CNMR, 145.47, 144.22, 143.95, 142.22, 139.27, 138.77, 
128.87, 127.75, 126.76, 61.55, 60.46, 32.94, 32.56, 31.96, 
29.09. 
Br 
Example 75 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(3-propanyl)]-bis-[5,6,7,8-tetrahydroquinolinium] 
dibromide 
Br 
40 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di -(3-propany I) ]-bis-[ 5 ,6, 7 ,8-tetrahydroisoquino-
linium] dibromide 
Br -
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 5,6,7,8-tetrahydroisoquinoline (3 mmol) in acetoni-
trile and the solution refluxed for 24 hours. The acetonitrile 
was removed in vacuum and the resulting residue was 
45 partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no 5,6,7,8-tetrahy-
droisoquinoline left in the aqueous layer. The resulting 
aqueous solution of the product was lyophilized to yield the 
pure product. (75%). 1H NMR (300 MHz, D20, ppm), 8.67 
50 (s, 2H), 8.60 (d, 1=6.3, 2H), 7.68 (d, 1=6.3, 2H), 7.48 (d, 
1=8.4, 4H), 7.29 (d, 1=8.4, 4H), 4.59 (t, 1=7.2, 4H), 2.94 (br, 
4H), 2.86 (br, 4H), 2.81 (t, 1=7.2, 4H), 2.39 (p, 1-7.5, 4H), 
1.74-1.85 (m, 10H), CNMR, 158.38, 143.86, 140.21, 
139.39, 138.64, 138.48, 128.86, 127.91, 126.56, 60.78, 
55 21.12, 32.00, 29.31, 26.22, 21.11. 
60 
Example 77 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(3-propanyl) ]-bis-( 4-methylpyridinium) dibro-
mide 
Br 
- 65 -
US 9,499,518 B2 
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-continued 
e 
2Br 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 4-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
10 
vacuum and the resulting residue was partitioned between 
70 
Example 79 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(3-propanyl)]-bis-(2-methylpyridinium) dibro-
mide 
(:) IN 
Br -
ether and water. The aqueous layer was washed extensively 
with ether until no 4-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 15 
ppm), 8.90 (d, 1=6.6, 4H), 7.85 (d, 1=6.3, 4H), 7.48 (d, 
1=8.4, 4H), 7.32 (d, 1=8.4, 4H), 4.68 (t, 1=7.5, 4H), 2.78 (t, 
1=7.8, 2.58 (s, 6H), 2.34 (m, 4H). CNMR, 159.77, 143.71, 
139.52, 138.51, 129.08, 128.73, 126.76, 60.72, 32.76, 31.91, 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu-
tion of 2-picoline (3 mmol) in acetonitrile and the solution 
20 refluxed for 24 hours. The acetonitrile was removed in 21.27. 
Example 78 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(3-propanyl)]-bis-(3-methylpyridinium) dibro-
mide 
25 yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 9.02 (d, 3=6.3, 2H), 8.40 (dt, 1=1.5, 1=7.8, 2H), 7.97 
(d, 1=7.8, 2H), 7.90 (t, 1=6.3, 2H), 7.53 (d, 1-8.1, 4H), 7.38 
(d, 1=8.1, 4H), 4.65 (t, 1=7.8, 4H), 2.86 (t, 1=7.8, 4H), 2.82 
(s, 6H), 2.24-2.32 (m, 4H) CNMR, 155.49, 145.33, 145.23, 
- 30 139.56, 138.54, 130.41, 129.21, 126.78, 125.89, 57.71, 31.93, 31.71, 19.75. 
~ 
~N 
35 
Example 80 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1-
ethandiyloxy) ]bis-ethyl }-bis-[3-(2'-S-1-methyl-pyr-
rolidin-2-yl)-pyridinium]dichloride 
4,4'-Bis-(3-bromo-propyl)-biphenyl was added to a solu- 1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy ]-ethoxy }-
tion of 3-picoline (3 mmol) in acetonitrile and the solution ethane was added to a solution of S-nicotine (3 mmol) in 
refluxed for 24 hours. The acetonitrile was removed in 55 acetonitrile and the solution refluxed for 24 hours. The 
acetonitrile was removed in vacuum and the resulting resi-
due was partitioned between ether and water. The aqueous 
60 
layer was washed extensively with ether until no S-nicotine 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 9.00 (s, 2H), 8.92 (d, 1=6.3, 2H), 8.35 (d, 1=7.8, 2H), 
7.93 (dd, 1=6.0, 1=8.1, 2H), 7.46 (d, 1=8.4, 4H), 7.32 (d, 
1=8.4, 4H), 4.72 (t, 1=7.5, 4H), 2.80 (t, 1=7.5, 4H), 2.50 (s, 
6H), 2.35-2.44 (m, 4H). CNMR, 146.06, 144.41, 141.92, 65 
139.82, 139.55, 138.42, 129.11, 127.61, 126.70, 61.45, 
32.76, 31.99, 17.80. 
left in the aqueous layer. The resulting aqueous solution of 
the product was lyophilized to yield the pure product. (75% ). 
1 H NMR (300 MHZ, D20, ppm), 8.63-6.64 (m, 4H), 8.38 ( d, 
1=8.1, 2H), 7.90 (dd, 1=7.8, d=6.6, 2H), 2.61-2.63 (m, 4H), 
3.85 (t, 1=4.8, 4H), 3.36-3.47 (m, 10H), 3.04-3.04 (m, 2H), 
2.20-2.38 (m, 4H), 2.04 (s, 6H), 1.60-1.84 6H). 
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Example 81 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiyloxy) ]bis-ethyl} -bis(2-methy lpyridinium) 
dichloride 
72 
-continued 
N/'......./o~o~o~NSl 
10 
2c1 8 # 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy ]-ethoxy }-
ethane was added to a solution of 4-picoline (3 mmol) in 
c1~0~o~0~c1 - acetonitrile and the solution refluxed for 24 hours. The 
G 8 
10 acetonitrile was removed in vacuum and the resulting resi-
o o due was partitioned between ether and water. The aqueous 
N~ ~0/'--..../ ~NI ~ layer was washed extensively with ether until no 4-picoline 
2
c
1 
e # left in the aqueous layer. The resulting aqueous solution of 
15 
the product was lyophilized to yield the pure product. (75% ). 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 2-picoline (3 mmol) in 
acetonitrile and the solution refluxed for 24 hours. The 
acetonitrile was removed in vacuum and the resulting resi-
20 
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no 2-picoline 
left in the aqueous layer. The resulting aqueous solution of 
the product was lyophilized to yield the pure product. (75%). 
1H NMR (300 MHz, D20, ppm), 8.55 (dd, 1=6.3, 1=1.2, 
2H), 8.23 (dt, 1=7.8, 1-1.5, 2H), 7.75 (d, 1=7.8, 2H), 7.68 (dt, 25 
1=7.8, 1=1.5, 2H), 4.62 (t, 4H), 3.82 (t, 4H), 3.40-3.44 (m, 
4H), 3.35-3.39 (m, 4H), 2.36 (s, 6H). 
Example 82 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiyloxy) ]bis-ethyl} -bis(3 -methy lpyridinium) 
dichloride 
CI~0~o~0~c1 -
30 
35 
N/'......./0~o~0~N8( 
I 0 4o 
2c1 8 # 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 3-picoline (3 mmol) in 
45 
acetonitrile and the solution refluxed for 24 hours. The 
acetonitrile was removed in vacuum and the resulting resi-
due was partitioned between ether and water. The aqueous 
layer was washed extensively with ether until no 3-picoline 
left in the aqueous layer. The resulting aqueous solution of 
50 
the product was lyophilized to yield the pure product. (75%). 
1H NMR (300 MHZ, D20, ppm), 8.54 (s, 2H), 8.49 (d, 
1=6.0, 8.22 (d, 1=8.1, 2H), 8.76 (dd, 1=8.1, 1=6.0, 2H), 4.57 
(t, 1=4.8, 4H), 3.84 (t, 1=5.1, 4H), 3.43-3.48 (m, 4H), 
3.35-3.39 (m, 4H), 2.69 (s, 6H). CNMR, 146.48, 144.22, 
55 
141.89, 139.81, 127.33, 69.93, 69.60, 68.95, 60.97, 17.89. 
Example 83 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiyloxy )]bis-ethyl }-bis( 4-methylpyridinium) 
dichloride 
CI~0~o~0~c1 -
60 
65 
1H NMR (300 MHz, D20, ppm), 8.47 (d, 1=6.9, 4H), 7.70 
(d, 1=6.3, 4H), 4.54 (t, 1=4.8, 4H), 3.83 (t, 1=4.8, 4H), 
3.43-3.47 (m, 4H), 3.35-3.38 (m, 4H), 2.47 (s, 6H). CNMR, 
160.56, 143.63, 128.52, 69.92, 69.57, 68.95, 60.27, 21.58. 
Example 84 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1-
ethandiyloxy) ]bis-ethyl} -bis( 5 ,6, 7,8-tetrahydroqui-
nolinium) dichloride 
CI~0~o~0~c1 -
N/'......./o~o~o~Na 
10 
2c1 8 # 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy ]-ethoxy }-
ethane was added to a solution of tetrahydroquinoline (3 
mmol) in acetonitrile and the solution refluxed for 24 hours. 
The acetonitrile was removed in vacuum and the resulting 
residue was partitioned between ether and water. The aque-
ous layer was washed extensively with ether until no tetra-
hydroquinoline left in the aqueous layer. The resulting 
aqueous solution of the product was lyophilized to yield the 
pure product. (75% ). 1 H NMR (300 MHZ, D20, ppm), 8.39 
(d, 1=6.3, 2H), 8.04 (d, 1=8.1, 2H), 7.55 (dd, 1=8.1, 1=6.3, 
2H), 4.57 (t, 1=4.5, 4H), 3.83 (t, 1=4.5, 4H), 4.43-3.49 (m, 
4H), 3.36-3.38 (m 4H), 2.98 (t, 6.3, 4H), 2.82 (t, 1=6.3, 4H), 
1.79-1.83 (m, 4H), 1.63-1.69 (m, 4H). CNMR, 154.58, 
145.92, 143.59, 139.99, 123.92, 70.19, 69.74, 68.40, 56.28, 
49.10, 28.72, 27.26, 21.40, 20.45. 
Example 85 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1-
ethandiyloxy) ]bis-ethyl} -bis( 5 ,6, 7, 8-tetrahydroiso-
quinolinium) dichloride 
CI~0~o~0~c1 -
CG./'......./o~o~o-......../'N80 10 2c1 8 # 
US 9,499,518 B2 
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1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of tetrahydroisoquinoline (3 
mmol) in acetonitrile and the solution refluxed for 24 hours. 
The acetonitrile was removed in vacuum and the resulting 
residue was partitioned between ether and water. The aque- 5 
ous layer was washed extensively with ether until no tetra-
hydroisoquinoline left in the aqueous layer. The resulting 
aqueous solution of the product was lyophilized to yield the 
pure product. (75%). 1H NMR (300 MHz, D20, ppm), 8.33 
(s, 2H), 8.24 (d, 1=6.3, 2H), 7.52 (d, 1=6.3, 2H), 4.47 (t, 10 
1=4.8, 4H), 3.81 (t, 1=4.8, 4H), 3.42-3.45 (m, 4H), 3.33-3.37 
(m, 4H), 2.81-2.84 (br, 4H), 2.70-2.74 (br, 4H), 1.63-1.70 
(m, 8H). CNMR, 159.33, 143.61, 140.12, 138.77, 127.74, 
69.96, 69.60, 69.02, 60.12, 29.40, 26.18, 20.98, 20.95. 
Example 86 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiy loxy) ]bis-ethy I}-bis- [3 -(3 -hydroxypropy I)-
pyridinium] dichloride 
cJ~0~o/'......./0~cl ____... 
15 
20 
CG
/'o......./o~o~o~NSCJ 25 
10 OH 2c1° # HO 
74 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHZ, D20, 
ppm), 8.72 (s, 2H), 8.65 (d, 1=6.0, 8.39 (d, 1=7.8, 2H), 7.91 
(t, 1=6.9, 2H), 4.69 (t, 1=4.8, 4H), 4.64 (s, 4H), 3.89 (t, 1=4.2, 
4H), 3.41-3.49 (m, 8H). 
Example 88 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1-
ethandiyloxy) ]bis-ethyl} -bis-(2,4-dimethy lpyri-
dinium) dichloride 
cJ~0~o/'......./0~cl ____... 
N~0~o~0~&N 10 
0 # 
2Cl 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy)-ethoxy ]-ethoxy }-
ethane was added to a solution of 2,4dimethylpyridine (3 
mmol) in acetonitrile and the solution refluxed for 24 hours. 
The acetonitrile was removed in vacuum and the resulting 
residue was partitioned between ether and water. The aque-
30 ous layer was washed extensively with ether until no 2,4di-
methylpyridine left in the aqueous layer. The resulting 
aqueous solution of the product was lyophilized to yield the 
pure product. (75%). 1H NMR (300 MHZ, D20, ppm), 3.35 
(d, 1=6.6, 2H), 7.58 (s, 2H), 7.50 (d, 1-6.6, 2H), 4.54 (t, 1-4.8, 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 3-(3-hydroxypropyl)-
pyridine (3 mmol) in acetonitrile and the solution refluxed 
for 24 hours. The acetonitrile was removed in vacuum and 
the resulting residue was partitioned between ether and 
water. The aqueous layer was washed extensively with ether 
until no 3-(3-hydroxypropyl)-pyridine left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1H NMR (300 
MHz, D20, ppm), 8.59 (s, 2H), 8.53 (d, 1=6.0, 8.29 (d, 
1=8.4, 2H), 7.81 (dd, 1=8.4, 1=6.0, 2H), 4.60 (t, 1-4.8, 4H), 
40 
3.85 (t, 1=4.5, 4H), 3.44-3.49 (m, 8H), 3.36-3.39 (m, 4H), 
2.76 (t, 1=7.8, 4H), 1.74-1.80 (m, 4H). CNMR, 145.99, 
144.09, 143.35, 142.35, 127.64, 69.96, 69.64, 68.96, 61.06, 
60.60, 31.21, 28.81. 
35 4H), 3.82 (t, 1=4.8, 4H), 3.41-3.45 (m, 4H), 3.34-3.36 (m, 
4H), 2.62 (s, 6H). 2.40 (s, 6H). CNMR, 159.76, 154.44, 
144.47, 130.31, 126.00, 70.16, 69.66, 68.42, 56.36, 49.10, 
21.27, 19.90. 
Example 87 
45 
Example 89 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2,1-
ethandiyloxy) ]bis-ethyl} -bis-(3,4-dimethy lpyri-
dinium) dichloride 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiy loxy) ]bis-ethy I} -bis-(3 -hydroxymethy lpyri-
dinium) dichloride cJ~
0~o/'......./0~cl -----
cJ~0~o/'......./0~cl ____... 
HOl)N~
0
~o/'......_/
0
~Nt:)OH I 0 I 0 
# 0 # 
2Cl 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 3-hydroxymethylpyridine 
60 
(3 mmol) in acetonitrile and the solution refluxed for 24 
hours. The acetonitrile was removed in vacuum and the 
resulting residue was partitioned between ether and water. 65 
The aqueous layer was washed extensively with ether until 
no 3-hydroxymethylpyridine left in the aqueous layer. The 
-continued 
N~o~o~o~NGX 
10 
0 # 
2Cl 
US 9,499,518 B2 
75 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 3,4-dimethylpyridine (3 
mmol) in acetonitrile and the solution refluxed for 24 hours. 
The acetonitrile was removed in vacuum and the resulting 
residue was partitioned between ether and water. The aque- 5 
ous layer was washed extensively with ether until no 3,4-
dimethylpyridine left in the aqueous layer. The resulting 
aqueous solution of the product was lyophilized to yield the 
pure product. (75%). 1H NMR (300 MHZ, D20, ppm), 8.36 
(s, 2H), 8.30 (d, 1=6.3, 2H), 7.61 (d, 1=6.3, 2H), 4.49 (t, 10 
1=4.8, 4H), 3.81 (t, 1=4.8, 4H), 3.42-3.45 (m, 4H), 3.34-3.37 
(m, 4H), 2.37 (s, 6H). 2.25 (s, 6H). CNMR, 159.23, 142.79, 
141.27, 138.49, 128.06, 69.92, 69.58, 69.01, 60.08, 49.07, 
19.75, 16.32. 
Example 90 
Synthesis of Compound N,N'-{ 2,2'-[ oxybis-(2, 1-
ethandiyloxy) ]bis-ethyl} -bis-(3 ,5 -dimethy lpyri-
dinium) dichloride 
CI~0~o~0~c1 -
N~
0
~o./'-....../
0
~NE( 
1(£1 
# 
2c1 8 
15 
20 
25 
30 
76 
ether and water. The aqueous layer was washed extensively 
with ether until no 2-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.58 (d, 2H), 8.18-8.24 (m, 2H), 7.65-7.74 (m 4H), 
4.40 (t, 4H), 2.68 (s, 6H), 2.21 (t, 4H), 1.84-1.94 (m, 4H), 
1.46-1.54 (m, 4H). CNMR, 155.29, 145.16, 144.78, 130.32, 
125.75, 77.89, 65.52, 57.61, 28.78, 24.44, 18.19. 
Example 92 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-(3-methylpyridinium) dichloride 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
of 3-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
35 ppm), 8.72 (s, 2H), 8.66 (d, 2H), 8.38 (d, 2H), 7.94 (dd, 2H). 
4.59 (t, 4H), 2.58 (s, 6H), 2.32 (t, 4H), 2.28 (p, 4H), 1.59 (p, 
4H). CNMR, 146.17, 143.83, 141.40, 140.11, 127.60, 77.95, 
65.54, 61.35, 30.00, 24.36, 18.22, 18.00. 
1-Chloro-2-{ 2-[2-(2-chloro-ethoxy )-ethoxy ]-ethoxy }-
ethane was added to a solution of 3,5-dimethylpyridine (3 
mmol) in acetonitrile and the solution refluxed for 24 hours. 
The acetonitrile was removed in vacuum and the resulting 
residue was partitioned between ether and water. The aque-
ous layer was washed extensively with ether until no 3,5-
dimethylpyridine left in the aqueous layer. The resulting 40 
aqueous solution of the product was lyophilized to yield the 
pure product. (75%). 1H NMR (300 MHz, D20, ppm), 8.34 
(s, 4H), 8.06 (s, 2H), 4.52 (t, 1=4.8, 4H), 3.83 (t, 1=4.8, 4H), 
3.42-3.46 (m, 4H), 3.35-3.38 (m, 4H), 2.31 (s, 12H). 
CNMR, 146.98, 141.42, 138.93, 69.95, 69.61, 69.01, 60.75, 45 
49.08, 17.68. 
Example 91 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-(2-methylpyridinium) dichloride 
50 
Br Br- 55 
~N 
lj 
2Br8 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
of 2-picoline (3 mmol) in acetonitrile and the solution 65 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
Example 93 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-( 4-methylpyridinium) dichloride 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
of 4-picoline (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 4-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.48 (d, 4H), 7.68 (d, 4H), 4.38 (t, 4H), 2.46 (s, 6H), 
2.18 (t, 4H), 1.86-1.98 (m, 4H), 1.34-1.44 (m, 4H). CNMR, 
160.12, 143.13, 128.77, 77.87, 65.47, 60.61, 29.86, 24.30, 
21.56, 18.17. 
US 9,499,518 B2 
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Example 94 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-(3,4-dimethylpyridinium) dichloride 
78 
-continued 
B cj 
2Br
8 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
of tetrahydroisoquinoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
15 with ether until no tetrahydroisoquinoline left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1H NMR (300 
MHZ, D20, ppm), 8.34 (s, 2H), 8.22 {d, 1=6.3, 2H), 7.54 (d, 
1-6.3, 2H), 4.31 (t, 1=7.2, 4H), 2.82-2.84 (br, 4H), 2.71-2.73 
of 3,4-Iutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.35 (s, 2H), 8.29 (d, 2H), 7.60 (d, 2H), 4.32 (t, 4H), 25 
2.38 (s, 6H), 2.24 (s, 6H), 2.16 (t, 4H), 1.86-1.94 (m, 4H), 
1.30-1.42 (m 4H). 
20 (br, 4H), 2.12 (t, 1=6.6, 4H), 1.81-1.91 (m, 4H), 1.64-1.69 
(m, 8H), 1.29-1.38 (m, 4H). CNMR, 158.94, 143.15, 139.67, 
139.05, 128.01, 77.81, 65.50, 60.46, 29.92, 29.41, 26.26, 
24.38, 21.02, 21.05, 18.20. 
Example 95 
30 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-(3,5-dimethylpyridinium) dichloride 
35 
Br 
'l I(+)# 40 
1,12-Dibromo-dodeca-5,7-diyne was added to a solution 
45 
of 3,5-lutidine (3 mmol) in acetonitrile and the solution 
refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3,5-lutidine left in the aqueous layer. The 
50 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.32 (s, 4H), 8.00 (s, 2H), 4.36 (t, 4H), 2.34 (s, 12H), 
2.18 (t, 4H), 1.86-1.94 (m, 4H), 1.34-1.44 (m, 4H). CNMR, 
146.62, 140.97, 139.15, 77.88, 65.41, 61.05, 29.88, 24.28, 55 
18.14, 17.70. 
Example 96 
Synthesis of Compound N,N'-(5,7-dodecadiyn-1,12-
diyl)-bis-(5,6,7,8-tetrahydroisoquinolinium) dichlo-
ride 
60 
Br 
Example 97 
Synthesis of Compound N,N'-[(1,4-phenylene)-bis-
( 4-butynyl)]-bis-(3-methyl-pyridinium) dibromide 
Br-
l;J 
2Br
8 
1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a 
solution of 3-picoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.67 (s, 2H), 8.60 ( d, 1=6.0 Hz, 2H), 8.25 ( d, 1=8.0 Hz, 
2H), 7.80 (dd, 1=6.0 Hz, 1=8.0 Hz, 2H), 7.14 (s, 4H), 4.63 
(m, 4H), 3.02 (t, 1=6.3 Hz, 4H), 2.36 (s, 6H). CNMR, 
146.68, 144.11, 141.66, 139.87, 131.59, 127.39, 122.22, 
86.10, 84.40, 59.68, 21.95, 17.90. 
Example 98 
Synthesis of Compound N,N'-[(1,4-phenylene)-bis-
( 4-butynyl)]-bis-( 4-methyl-pyridinium) dibromide 
65 Br Br-
Br Br-
US 9,499,518 B2 
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79 
-continued 
2Br
0 
1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a 
solution of 4-picoline (3 mmol) in acetonitrile and the 10 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 4-picoline left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 15 
yield the pure product. (75%). 1H NMR (300 MHz, D20, 
ppm), 8.60 (d, 1=6.6 Hz, 4H), 7.73 (d, 1=6.6 Hz, 4H), 7.15 
80 
-continued 
~J 
~ 
-......._--==~~ '')----~~ 
2Br
0 
1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a 
solution of 3,4-lutidine (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3,4-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHZ, D20, 
ppm), 8.50 (s, 2H), 8.44 (d, 1-6.3 Hz, 2H), 7.65 (d, 1=6.3 Hz, (s, 4H), 4.60 (t, 1=6 Hz, 4H), 3.01 (t, 1=6.0 Hz, 2.49 (s, 6H). 
CNMR, 160.87, 143.41, 131.58, 128.57, 122.26, 86.16, 
84.25, 59.03, 21.87, 21.68. 20 
2H), 7.13 (s, 4H), 4.57 (t, 1=6.3 Hz, 4H), 2.99 (t, 1=6.3 Hz, 
4H), 2.38 (s, 6H), 2.24 (s, 6H). 
Br 
Example 99 
Synthesis of Compound N,N'-[(1,4-phenylene)-bis-
( 4-butynyl) ]-bis-(5,6, 7,8-tetrahydroisoquiolinium) 
dibromide 
Br-
f ' 
25 
30 
Br 
Example 101 
Synthesis of Compound N,N'-[(1,4-phenylene)-bis-
( 4-butynyl)]-bis-(3,5-dimethyl-pyridinium) dibro-
mide [ZZ 1 111] 
Br-
f ' + 8 I<±># 35 ~ + l? I<±># '7 
2Br
0 
1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a 
solution of terahydroisoquinoline (3 mmol) in acetonitrile 
and the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no terahydroisoquinoline left in 
the aqueous layer. The resulting aqueous solution of the 
product was lyophilized to yield the pure product. (7 5% ). 1 H 
NMR (300 MHz, D20, ppm), 8.46 (s, 2H), 8.35 (d, 1=6.6 
Hz, 2H), 7.56 (d, 1=6.6 Hz, 2H), 7.09 (s, 4H), 4.54 (t, 1=6.3 
Hz, 4H), 2.98 (t, 1-6.3 Hz, 4H), 2.83 (t, 1=6.0 Hz, 4H), 2.66 
(t, 1=5.4 Hz, 4H), 1.64-1.68 (m, 8H). 
Example 100 
Synthesis of Compound N,N'-[(1,4-phenylene)-bis-
(4-butynyl)]-bis-(3,4-dimethyl-pyridinium) dibro-
mide [ZZ-1-110] 
40 
45 
2Br
0 
1,4-Bis-(4-bromo-but-1-ynyl)-benzene was added to a 
solution of 3,5-lutidine (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 3,5-lutidine left in the aqueous layer. The 
resulting aqueous solution of the product was lyophilized to 
yield the pure product. (75%). 1H NMR (300 MHZ, D20, 
50 
ppm), 8.46 (s, 4H), 8.04 (s, 2H), 7.11 (s, 4H), 4.59 (t, 1=6.3 
Hz, 4H), 2.99 (t, 1=6.3 Hz, 4H), 2.29 (s, 12H). CNMR, 
147.17, 141.31, 138.96, 131.59, 122.24, 86.31, 84.46, 59.45, 
21.99, 17.73. 
55 
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Example 102 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(1-propyn-3-yl)]-bis-(3-methylpyridinium) dibro-
mide 
Br -Br Br - 65 Br 
US 9,499,518 B2 
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-continued 
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4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was 
added to a solution of 3,4-lutidine (3 mmol) in acetonitrile 
and the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
5 between ether and water. The aqueous layer was washed 
extensively with ether until no 3,4-lutidine left in the aque-
ous layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75% ). 1 H NMR (300 
MHz, d6-DMSO, ppm), 9.02 (s, 2H), 8.88 (d, 2H), 8.0 (d, 
4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was 
added to a solution of3-picoline (3 mmol) in acetonitrile and 
the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no 3-picoline left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1H NMR (300 
MHz, d6-DMSO, ppm), 9.16 (s, 2H), 9.12 (s, 2H), 8.54 (d, 15 
2H), 8.22 (dd, 2H), 7.8 (d, 4H), 7.62 (d, 4H), 5.8 (s, 4H), 2.4 
10 2H), 7.8 (d, 4H), 7.6 (d, 4H), 5.9 (s, 4H), 2.46 (s, 6H), 2.40 
(s, 6H). CNMR, 159.64, 143.10, 141.96, 140.39, 138.65, 
133.12, 128.88, 127.68, 120.88, 88.83, 83.08, 50.41, 20.66, 
17.19. 
(s, 6H). CNMR, 147.52, 144.53, 142.46, 140.44, 139.73, 
133.14, 128.36, 127.69, 120.85, 89.16, 82.81, 51.19, 18.79. 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 
departing from the spirit and scope of the invention. All such 
modifications and variations are intended to be included 
Example 103 herein within the scope of this disclosure and the present 
20 invention and protected by the following claims. 
Br 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(1-propyn-3-yl)]-bis-(4-methylpyridinium) dibro-
mide 
Br -
Q e ~ Br 
25 
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Example 105 
Persistent Inflammatory Pain Model 
A rat model of tonic inflammatory pain (the formalin test) 
was used in this study (Wheeler-Aceta and Cowan, 1991). 
Fifty ul offormalin (5%) was injected subcutaneously (SC) 
into the dorsal surface of the left hind paw. This procedure 
typically produces a biphasic behavioral response consisting 
of flinching, lifting and licking. The first phase (0-10 min) is 
thought to result from direct stimulation of nociceptors 
(nociceptive pain) whereas the second phase (20-60 min) is 
thought to involve central sensitization resulting from con-
tinued activation of receptors (TRPA1) with an important 
role in inflammatory pain. Rats were pretreated 15 min prior 
to formalin (SC) injection with ZZ-16-1C as synthesized in 
Example 104 and administered by the I.P. route. Saline 
served as control. Incidences of formalin-induced flinching 
40 were counted continuously in 5 min intervals for 60 min. 
4,4'-Bis-(3-bromo-prop-1-ynyl)-biphenyl (1 mmol) was 
added to a solution of 4-picoline (3 mmol) in acetonitrile and 
the solution refluxed for 24 hours. The acetonitrile was 
removed in vacuum and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no 4-picoline left in the aqueous 
layer. The resulting aqueous solution of the product was 
lyophilized to yield the pure product. (75%). 1H NMR (300 
MHZ, d6 -DMSO, ppm), 9.05 (d, 4H), 8.06 (d, 4H), 7.78 (d, 45 
4H), 7.62 (d, 4H), 5.8 (s, 4H), 2.62 (s, 6H). CNMR, 160.67, 
144.10, 140.41, 133.11, 129.27, 127.69, 120.85, 89.06, 
82.97, 50.56, 22.39. 
Example 104 
Synthesis of Compound N,N'-[(1,1 '-biphenyl)-4,4'-
di-(1-propyn-3-yl)]-bis-(3,4-dimethylpyridinium) 
dibromide [ZZ-1-61 C] 
Br -
v~ 
Each rat received only one treatment. The results are pre-
sented in FIGS. 1 and 2. FIG. 1 shows the time course of the 
effect of intraperitoneal administration of varying doses of 
ZZ-16-1 C in the rodent model of tonic inflammatory pain. 
The drug produced a decrease in the number of twitches in 
both phases of the formalin test indicating it's a analgesic 
effect in this. The effect of the drug remained significant 
even at 60 min. FIG. 2 shows the dose response effect of 
ZZ-16-1 C following intraperitoneal administration in the 
50 rodent model of tonic inflammatory pain. The effect of the 
drug was dose-related. Both phases of the formalin test were 
affected, however, ZZ-6-1C was more effective in phase 2 
than phase 1. 
55 
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Example 106 
Study of the Anti-Hyperalgesic Effects of 
ZZ-1-61 C Following Intraperitoneal Administration 
in a Rodent Model of Chemotherapy-Induced Pain 
~ 65 
A study was performed to screen the analgesic activity of 
ZZ-1-61 C following administration by the intraperitoneal 
(IP) route in the rodent model of chemotherapy-induced 
pain. A well accepted preclinical model of neuropathic pain 
that produced enhanced pain sensitivity similar to that 
observed as a result of chemotherapy administration in 
humans was employed (Polomano and Bennett, 2001 ). Rats 
US 9,499,518 B2 
83 84 
with hypersensitivity to pain as a result of nerve damage 
induced by the vincristine accompanied by weight loss. The 
ability of ZZ-1-61C to prevent chemotherapy-induced tox-
icity manifested as weight loss was determined as follows. 
Male rats (N=6) were given 100 ug/kg of ZZ-1-61C in 
combination with vincristine. The control group (N=6) was 
were injected (IP) with vincristine, a vinca alkaloid anti-
tumor agent, using two 5-day cycles (100 ug/kg/day). Rats 
typically develop a neuropathic pain state with hypersensi-
tivity to pain as a result of nerve damage induced by the 
vincristine. The ability of ZZ-1-61C to prevent chemo- 5 
therapy-induced neuropathic pain was determined as fol-
lows. Male rats (N=6) were given 100 ug/kg ofZZ-1-61C in 
combination with vincristine. The control group (N=6) was 
given vincristine alone. Mechanical hyperalgesia was 
assessed employing the paw pressure test (32 g/sec, 300 g 
cut-off) as described by Randal and Selitto (1957) using a 
Basile Analgesimeter (UGO Basile, Italy) with vocalization 
given vincristine alone. Body weight was assessed on a daily 
10 basis. The results are presented in FIG. 5. The ZZ-1-61 C was 
as an end-point. The results are presented in FIG. 3. The 
ZZ-1-61C was effective in blocking the development of 
chemotherapy-induced neuropathic pain (anti-hyperalgesic 15 
effect) by the vincristine. 
Example 107 
Study of the Anti-Allodynic Effect of ZZ-1-61 C 
Following Intraperitoneal Administration in a 
Rodent Model of Chemotherapy-Induced Pain 
20 
able to obtund the weight loss in the rats normally seen as 
a result of vincristine administration in the chemotherapy-
induced pain model. 
Example 109 
Bis Analogs Ability to Block a9a 10 nAChR 
Bis analogs were tested for their ability to block a9a 10 
nAChRs. Cloned nAChR subunits were heterologously 
expressed in Xenopus oocytes, voltage-clamped and 
A study was performed to screen the analgesic activity of 
ZZ-1-61 C following administration by the intraperitoneal 
(IP) route in the rodent model of chemotherapy-induced 
pain. A well accepted preclinical model of neuropathic pain 
that produced enhanced pain sensitivity similar to that 
observed as a result of chemotherapy administration in 
humans was employed (Polomano and Bennett, 2001). Rats 
were injected (IP) with vincristine, a vinca alkaloid anti-
tumor agent, using two 5-day cycles (100 ug/kg/day). Rats 
typically develop a neuropathic pain state with hypersensi-
tivity to pain as a result of nerve damage induced by the 
vincristine. The ability of ZZ-1-61C to prevent chemo-
therapy-induced neuropathic pain was determined as fol-
lows. Male rats (N=6) were injected with vincristine as 
describe above. The rats were then given ZZ-1-61 C at a dose 
25 exposed to ACh and compounds as previously described in 
Vincler, M. et a!., Molecular mechanism for analgesia 
involving specific antagonism of alpha9alpha1 0 nicotinic 
acety !choline receptors, Proc Nat! A cad Sci USA 2006, 103: 
30 17880-17884 and Cartier G E eta!., A new alpha-Conotoxin 
which targets alpha3best2Nicotinic Acetylcholine Recep-
tors, J. Bioi. Chern. 1996, 271:7522-7528. Briefly, the 
oocyte chamber consisting of a cylindrical well ( -30 fll in 
35 
volume) was gravity perfused at a rate of -2 ml/min with 
ND96 containing 0.01% (wt/vol) BSA. Oocytes were 
exposed once a minute to 1 sec pulses of ACh. The ACh 
concentration was 10 f.LM. Compounds were applied at the 
of 100 ug/kg following completion of the chemotherapy 
regimen. A second group of rats (N=6) was given vincristine 
alone. The control group received saline. Rats were placed 
beginning of a 5 min static bath incubation. The %block was 
40 
calculated as a% ofND96 control (no compound) response. 
on an elevated mesh floor and von Frey Filaments (Stoelting, 
Wood Dale, Ill.) with bending forces of 4 g and 15 gm were 
applied to the plantar surfaces of both hind paws. A positive 
response was regarded as a sharp withdraw! of the paw. The 45 
results are presented in FIG. 4. The ZZ-1-61C was effective 
in reducing the allodynia (anti-allodynic effect) produced by 
vincristine. 
Example 108 
Study of the Effect of ZZ-1-61C on the Toxicity 
(Body Weight Loss) of Vincristine in a Rodent 
Model of Chemotherapy-Induced Pain 
A study was performed to assess the ability of ZZ-1-61C 
50 
55 
to prevent loss of body weight typically induced by vincris-
tine follow administration in a rodent model of chemo-
therapy-induced pain. A well accepted preclinical model of 60 
neuropathic pain that produced enhanced pain sensitivity 
similar to that observed as a result of chemotherapy admin-
istration in humans was employed (Polomano and Bennett, 
2001 ). Rats were injected (IP) with vincristine, a vinca 
65 
alkaloid anti-tumor agent, using two 5-day cycles (100 
ug/kg/day). Rats typically develop a neuropathic pain state 
Results are shown in Table I. SEM represents the standard 
error of the mean. The results indicate that bis compounds 
consisting of a variety of different structures are activity at 
blocking a9a 10 nAChRs, the therapeutic target. 
TABLE I 
%Block 
Compound at 100 nM SEM 
GZ 585 B 68.9 8.6 
GZ 582 B 72.0 3.9 
GZ 581 B 68.7 5.8 
GZ 584 B 28.0 6.9 
GZ 581 A 32.4 16.9 
GZ 584A -24.4 10.2 
GZ 578 B 37.3 7.7 
GZ 570 B 23.1 11.9 
GZ 571 A 58.4 6.7 
GZ 579 B 62.5 6.6 
zz 1 81 63.3 11.3 
zz 1 82 2.9 9.9 
zz 1 110 89.4 4.6 
zz 1 111 23.8 8.3 
ZZ 55 G 65.4 9.8 
zz 55 c 10.7 10.8 
ZZ 1 55 D -13.8 4.6 
zz 161 c 91.9 6.1 
85 
f GZ-Compounds Structures o 
II 
e Br 
e I ::::,... 
Br e 
#' e Br 
& ::::,... 
Br e 
#' e Br 
9 499 518 B2 us ' ' 
GZ-585 B 
5 
10 
15 
20 
25 
GZ 582 B 
30 
35 
00 N 40 
45 
GZ581 B 
50 
55 
~ I# 
60 
65 
86 
-continued 
e Br 
& 
N 
e Br 
e Br 
w 
N 
e Br 
~ rv 
e Br 
BrH 
~~~ y 
e((l 
<±> N::::,... 
GZ584B 
GZ 581 A 
GZ 584A 
GZ 578 B 
87 
-continued 
~ rv 
II 
0 Br 
0 Br 
+ fP 
+ lp 
B # 
0 Br 
US 9,499,518 B2 
GZ 570 B 
10 
15 
GZ 571 A 20 
25 
30 
35 
Structures of ZZ-Compounds 
~ 0 2 Br 
y 
0 
2 Br 
f ' a I~ 
0 
2 Br 
88 
-continued 
8 I N 
0 
Br 
GZ 579 B 
ZZ-181 
zz 182 
ZZ-1-110 
US 9,499,518 B2 
89 
-continued 
~ 
HO~~ 
~ 
~~ 
A 
~~ 
e 
Br 
We claim the following: 
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2 Br 
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e 
2 Br 
e 
Br 
1. A method of blocking the nicotinic acetylcholine recep-
tor a9alOnAChR, comprising administering to a mamma-
lian subject in need thereof a pharmaceutically acceptable 
amount of a compound-of Formula (I) 
X 2 8EBR1-H2 C-L
1-Q-L2 -CH2-R
2EB8X 1 (I) 
wherein X18' and X28' are each independently an organic 
or inorganic anion; and 
45 
50 
55 
I~ o/ 
~ N 
~ 
r~ 
90 
~ N OH 
zz 1111 
ZZ55 G 
zz 55 c 
ZZ 155 D 
zz 161 c 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen; and R11 is hydrogen; or 
R1Eil and R2 Eil are 
+ 
CO
N:: 
# 
or 
wherein -L1-Q-L2 - is -(CH2 ) 4 -1,2-phenyl-(CH2 ) 4-; 
R1Eil and R2 Eil are rings represented by the formula or 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
60 
65 
wherein -L1-Q-L2 - is -(CH2) 4 -1,3-phenyl-(CH2) 4-; 
R1Eil and R2 Eil are rings represented by the formula 
or 
or 
US 9,499,518 B2 
91 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen or methyl; and R11 is 
hydrogen; or R1Eil and R2 Eil are 
+ 
CO
N:: 
# or 
wherein -L1-Q-L2 - is -(CH2 k1,4-phenyl-(CH2 ) 3-; 
R1Eil and R2 Eil are rings represented by the formula 
10 or 
15 
20 
92 
+ 
CO
N:: 
# or 
wherein -L1-Q-L2 - is -(CH~2-C C-1,2-phenyl-
C C-(CH2 ) 2-; R
1Eil and R2 are rings represented 
by the formula 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
25 methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen or methyl; and R11 is 
hydrogen; or R1Eil and R2 Eil are 
30 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
35 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen; and R11 is hydrogen; or 
R1Eil and R2 Eil are 
+ 
40 
CO
N:: 
# or 
45 
50 
wherein -L1-Q-L2 - is -(CH2 ) 2 -4,4'-biphenyl-(CH2 ) 2-; 
R1Eil and R2 Eil are rings represented by the formula 
55 
60 
wherein R3 is hydrogen or methyl; R5 is hydrogen, ethyl, 
butyl, phenyl, 1-methyl-2-pyrrolidinyl, bromo, 
hydroxymethyl or hydroxypropyl; R7 is hydrogen or 65 
methyl; R9 is hydrogen or methyl; and R 11 is hydrogen; 
or R1Eil and R2 Eil are 
or 
+ 
CO
N:: 
# or 
wherein -L1-Q-L2 - is -(CH~2-C C-1,3-phenyl-
C C-(CH2 ) 2-; R
1Eil and R2 are rings represented 
by the formula 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen or methyl; and R11 is 
hydrogen; or R1Eil and R2 Eil are 
+ 
CO
N:: 
# or 
or 
or 
US 9,499,518 B2 
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wherein -L1-Q-L2- is ---CH2---C C-1,4-phenyl-C==C-
CH2-; R1Eil and R2Eil are rings represented by the 
formula 
10 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 15 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen or methyl; and R11 is 
hydrogen; or R1Eil and R2Eil are 
20 
+ 25 
or 
94 
!ian subject in need thereof a pharmaceutically acceptable 
amount of a compound selected from the group consisting 
of: 
N,N'[ 1 ,4-phenylenedi-( 4-butanyl) ]-bis-(3,4-dimethyl-
pyridinium) dibromide; 
1 ,2-bis-[ 5-(3,4-dimethyl-pyridinium)-pent-1-ynyl]-ben-
zene dibromide; 
1 ,2-bis-[ 5-(3,5-dimethyl-pyridinium)-pent-1-ynyl]-ben-
zene dibromide; 
1 ,2-bis-[ 5-isoquinolinium-pent-1-ynyl)-benzene dibro-
mide; 
1,2-bis-[5-(3,4-dimethyl-pyridinium)-pentyl]-benzene 
dibromide; 
1 ,2-bis- [ 5-isoquinolinium -penty 1)-benzene dibromide; 
1 ,3-bis-[ 5-(3,4-dimethyl-pyridiniiim)-pent-1-ynyl]-ben-
zene dibromide; 
1 ,3-bis-(5-quinolinium-pent-1-ynyl)-benzene dibromide; 
1,3-bis-[5-(3,4-dimethyl-pyridinium)-pentyl]-benzene 
dibromide; 
1 ,3-bis-( 5-isoquinolinium -penty 1)-benzene dibromide; 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(3-propanyl)]-bis-[3-(3-hy-
droxy-propyl)-pyridinium] dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-(3,4-dim-
ethyl-pyridinium) dibromide; 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl)]-bis-(3,5-dim-
ethyl-pyridinium) dibromide; and 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di -(1-propyn-3-yl)]-bis-(3,4-
dimethylpyridinium) dibromide. CO
W-
# 3. The method of claim 2, wherein the compound is 
N,N'-[ (1, 1 '-biphenyl)-4,4'-di-(1-propyn-3-yl) ]-bis-(3,4-dim-
30 ethylpyridinium) dibromide. 
wherein -L1-Q-L2- is ---C C-4,4'-biphenyl-C C-; 
R1Eil and R2Eil are rings represented by the formula 
4. The method of claim 2, wherein the compound is 
N,N'-[ (1 ,4-phenylene )-bis-( 4-butynyl) ]-bis-(3,4-dimethyl-
pyridinium) dibromide. 
5. The method of claim 1, wherein -L1-Q-L2- is 
35 -(CH2)4 -1,2-phenyl-(CH2)4- and R
1
Eil and R2Eil are each 
40 
wherein R3 is hydrogen or methyl; R5 is hydrogen, 
methyl, ethyl, butyl, phenyl, 1-methyl-2-pyrrolidinyl, 
45 
bromo, hydroxymethyl or hydroxypropyl; R7 is hydro-
gen or methyl; R9 is hydrogen or methyl; and R11 is 
hydrogen; or R1Eil and R2Eil are 
+ 
50 
CO
W-
# or 
55 
+ 
CO
W-
. 
6. The method of claim 1, wherein X 18' and X28' are each 
bromide, -L1-Q-L2- is -(CH2)4 -1,2-phenyl-(CH2)4-, and 
R1Eil and R2Eil are each 
+ 
CO
W-
. 
2. A method of blocking the nicotinic acetylcholine recep-
tor a9a10nAChR, comprising administering to a mamma- * * * * * 
